Glia Responsivity in Nicotine Dependence by Adeluyi, Adewale Oluwamuyiwa
GLIA RESPONSIVITY IN NICOTINE DEPENDENCE 
by 
Adewale Oluwamuyiwa Adeluyi 
Bachelor of Pharmacy 
University of Ibadan, 2008 
Master of Public Health 
University of South Carolina, 2014 
 
Submitted in Partial Fulfilment of the Requirements 
For the Degree of Doctor of Philosophy in  
Pharmaceutical Sciences 
College of Pharmacy  
University of South Carolina 
2019 
Accepted by: 
Jill Turner, Major Professor 
Michael Wyatt, Chair, Examining Committee 
Lorne Hofseth, Committee Member 
Jeff Twiss, Committee Member 
Pavel Ortinski, Committee Member 
James Chou, Committee Member 



























I dedicate this work to Almighty God that has brought me this far. To the memory 
of my late parents, Emmanuel Adeluyi and Grace Adeluyi, who besides their 
numerous sacrifices, taught me to never give up, keep my eye on the prize, and 
work hard. Together, they left me a legacy that is the bedrock of my success.  
         To my siblings – Adekemi Adeluyi, Aderonke Adeluyi, Adeola Adeluyi (late), 
Adenike Adeluyi, and Adedotun Adeluyi, who are always there for me. We are knit 
together, and I cannot ask for a better five.  
         To my wife, Mayomi, for being part of this journey. Finally, to my adorable 
son, Tobiah Adeluyi, for bringing one of the best moments in my life and supporting 













First, I would like to thank my advisor, Dr. Jill Turner for her guidance, training, and 
immense support during the course of my graduate work. Her mentorship is so 
invaluable, I cannot ask for anything better. Her readiness to allow me to explore 
and apply data science to my research represents a defining moment in my 
graduate program. She also gave me an amazing opportunity to be part of a 
fabulous lab and I am extremely happy and grateful to have learnt a lot from one 
of the best.  
          I would also like to thank my committee members, Dr. Michael Wyatt (Chair), 
Dr. Lorne Hofseth, Dr. Jeff Twiss, Dr. Pavel Ortinski, and Dr. James Chou, for their 
extremely helpful insight and suggestions, in addition to their encouragement 
throughout the course of this project. Together, you have all shaped me into a 
better scientist. 
          I would also like to acknowledge my amazing lab colleagues, Dr. Miranda 
Fisher and Erin Anderson for their help with science-related issues and 
encouragement during the course of this work. I would not forget to mention the 
past members of our lab, Dr. Luyi Zhou and Lindsey Guerin, for their help in lab-
related matters.  
          Further, I would like to thank people who have collaborated with me on 
different projects or assisted me at some points during the course of my program. 
Particularly, Dr. Shannon Davis, Dr. Linnea Freeman, Dr. Sherine Chan, Ashley
 v 
 Galloway, Dr. Bernadette O’ Donovan, Dr. Rob Cole. I would also like to 
appreciate Dr. Seung Joon Lee and Dr. Changlong Liu, who both helped me at 
different points in my project. 
Finally, I would like to thank my friends who have more or less become a 
family, Babatunde Oyelowo, Eniola Olatunji, Ada Obi and Nefe Omofuma. Thank 
you all for your unflinching support all through the years. 
 vi 
ABSTRACT 
Neurons are the primary research target in the exploration and development of 
novel smoking cessation pharmacotherapies over the years. These research 
efforts have led to the discovery and development of three FDA-approved smoking 
cessation aids – nicotine replacement therapy, varenicline, and bupropion, each 
of which have quantifiable success as smoking cessation aids. However, relapse 
is still very common and smoking cessation is successful in less than 5% of quit 
attempts, making paramount the development of novel therapeutics. One 
untapped therapeutic target are glia, particularly, astrocytes and microglia, which 
are active participants in the neuroplastic events underlying drug addiction. 
         First, we examined microglial changes in the striatum – a mesolimbic brain 
region implicated in both the rewarding effects of drugs and the affective 
disruptions occurring during drug withdrawal. We show that chronic nicotine and 
withdrawal induce microglial activation accompanied with distinct expression of 
pro-inflammatory cytokines in the nucleus accumbens.  Nicotine withdrawal-
related pro-inflammatory effects accompany activation of microglia-related 
NADPH Oxidase 2 (Nox2) and induction of reactive oxygen species (ROS). Both 
cellular correlates of inflammation and increased anxiety-like behaviors occurring 
during nicotine withdrawal are absent following microglial depletion with colony 
stimulating factor 1 receptor inhibitor, PLX5622.
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         Based on these findings, we extended our study to capture tissue-level 
transcriptome-wide responses in the nucleus accumbens during chronic nicotine 
and withdrawal (24 h and 48 h). We show temporally-dependent activation of 
distinct gene programs in the nucleus accumbens during nicotine withdrawal. 
Differential gene expression analysis suggests that chronic nicotine treatment 
activates subset of genes that are neuroprotective while withdrawal from nicotine 
provokes neuroinflammation and oxidative stress-related transcriptional programs 
in the nucleus accumbens 
         To have a finer resolution that aid better characterization of transcriptomic 
changes, we performed cell type-specific RNA sequencing and evaluated 
astrocyte- and microglia-specific transcriptome changes during nicotine treatment 
and 48 h withdrawal. We show that gene programs associated with 
neuroinflammation were suppressed in microglia following chronic nicotine 
treatment while nicotine withdrawal triggers microglial pro-inflammatory networks. 
Further, whole transcriptome data suggest astrocytes assume a reactive 
phenotype during nicotine withdrawal. 
         Taken together, this work provides the first evidence of microglia involvement 
in nicotine dependence. In addition, our transcriptomic studies offer a less complex 
insight into the role of nucleus accumbal glia in nicotine dependency, pioneering 
future exploration of glia modulators as potential therapeutic targets for the 
development of smoking cessation therapeutics.
 viii 
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1.1    GENERAL OVERVIEW OF NICOTINE DEPENDENCE 
Tobacco smoking is the principal cause of preventable disease and premature 
death in the world. Globally, over 5 million premature deaths are attributable to 
tobacco smoking every single year, and nearly one-tenth – about 480,000, of these 
deaths occur in the United States (Changeux 2010, Reitsma et al 2017). Despite 
decreased smoking prevalence in the United States over the last decade, the 
disease burden attributable to tobacco smoking continues to rise. This is due in 
part to population growth, but also the high failure rate in quit attempts made by 
current smokers (Ng et al 2014).  
         Currently, over 42 million Americans still smoke, and nearly 80% of these 
smokers have made serious attempts to quit without success (Benowitz 2010). 
While quitting smoking significantly reduces the risk of smoking-related disease 
and death, successful smoking cessation remains a major challenge in the United 
States with only 3% success rate in quit attempts each year (Benowitz 2010, 
Changeux 2010). Today, it has become clearer that effects of nicotine and its 
withdrawal (during smoking cessation) on neural circuits relevant in nicotine 
dependence are more complex than initially thought. Therefore, in this chapter, I 
will discuss the molecular effects of nicotine, highlighting some of these effects in 
a well-defined neurocircuitry of addiction. Further, I will review the symptomology 






1.2    NEUROBIOLOGY OF NICOTINE DEPENDENCE  
Nicotine and Neuronal Nicotinic Acetylcholine Receptors (nAChRs) – Acute 
Effects 
Nicotine is the major psychoactive component in tobacco that drives the 
neurobiological effects underlying the sustainment and reinforcement of tobacco 
smoking (Balfour 2008, Benowitz 2010, Grunberg 2007). Smoke particles 
containing nicotine are inhaled into the lungs, where about 90% of nicotine present 
in the inhaled smoke is immediately absorbed into the pulmonary venous 
circulation (Jiloha 2014). Following absorption, it takes seven seconds for nicotine 
to reach the brain (Jiloha 2010), where it binds and activates nicotinic acetylcholine 
receptors (nAChRs). These receptors are ionotropic and are comprised of 5 
subunits.  There are 12 nAChR subunits expressed in the mammalian brain, 
including α2 - α10 and β2 - β4. Neuronal nAChRs can exist as either homomeric 
nAChR subtypes, in which all subunits are the same (i.e., α7 nAChRs), or as 
heteromeric nAChR subtypes, which are a mix of different subunits (i.e., α4β2 
nAChRs). This varying subunit composition influences the pharmacological 
features of nAChRs, and ultimately their responses to nicotine stimulation 
(D'Souza & Markou 2011, Govind et al 2009). For example, evidences from 
preclinical studies have indicated that α4-, α5-, α6-, α7-, and β2-containing 
nAChRs mediate the reinforcing and behavioral effects of nicotine (Fowler et al 
2008).  
Activation of nAChRs opens the cationic channel, allowing passage of 
potassium, sodium and calcium ions. Because nAChRs are preferentially located 
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at the presynaptic terminal, their effects are primarily modulatory and result in the 
release of nearly every major neurotransmitter (Benowitz 2010, Markou 2008). 
This results in a diverse array of effects.  For example, dopamine, one of the 
several neurotransmitters released following nAChR activation, is highly linked to 
nicotine’s reinforcing and rewarding properties (Jiloha 2010, Volkow & Li 2004). 
Other neurotransmitters modulated by nAChRs include γ-aminobutyric acid 
(GABA), β-endorphin, glutamate, serotonin, acetylcholine, and norepinephrine 
(Jiloha 2010). The release of GABA or β-endorphins results in attenuation of 
anxiety and tension (Benowitz 1999). Increased levels of glutamate enhance 
learning and memory, while serotonin release is connected to mood modulation 
and appetite suppression (Benowitz 1999). Both acetylcholine and norepinephrine 
modulate arousal but in addition, the release of acetylcholine enhances cognition 
while increased norepinephrine levels suppress appetite (Benowitz 1999). 
nAChRs’ propensity to promote release of myriad neurotransmitters following their 
activation provides a functional basis for nicotine’s modulation of various behaviors 
(Benowitz 2008a).   
 
Nicotine and Neuronal Nicotinic Acetylcholine Receptors (nAChRs) – 
Chronic Effects 
Chronic nicotine exposure results in numerous neuroadaptations within the brain. 
One prime example is the canonical subtype-specific upregulation of nAChRs 
(Buisson & Bertrand 2001, Changeux et al 1984). The term “upregulation” 
describes the persistent increase in nAChR radio-ligand binding sites in the brain 
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following long-term nicotine exposure. It is noteworthy that the receptor binding 
affinity of nicotine depends on nAChR subunit composition, which ultimately 
influence Ca2+ permeability as well as the tendency and extent of nicotine-induced 
upregulation. For example, a large percentage (~90%) of high affinity nicotine 
binding sites in the brain are made up of α4 and β2 subunits (Whiting & Lindstrom 
1988). In addition, studies have shown that incorporation of β4 into α6- or α3-
containing nAChRs leads to a remarkable degree of upregulation by nicotine, while 
the presence of α5- or α3-subunits in b2-contatining nAChRs seems to block 
upregulation by nicotine (Govind et al 2009). Several molecular mechanisms have 
been proposed for nicotine-induced upregulation of nAChR subtypes. First, unlike 
acetylcholine, nicotine is not a substrate for acetylcholine esterase hydrolytic 
degradation. As a result, nicotine’s presence and activity are prolonged, which 
consequently leads to nAChRs desensitization. The suggested neuronal adaptive 
response to long-term desensitization of nAChRs is upregulation (Picciotto et al 
2008, Wonnacott 1990). In contrast, another study demonstrated that nicotine-
induced nAChR upregulation is an intrinsic attribute of the nAChR protein rather 
than the suggested adaptive response of neurons expressing these receptors 
(Peng et al 1994). In support, they showed that upregulation results from 
decreased surface nAChR turnover, which is associated with nicotine-induced 
changes in nAChR conformation (Peng et al 1994). Another proposed mechanism 
for nicotine-induced upregulation is nicotine’s blockade of nAChR degradation 
through modulation of proteasomal activity (Ficklin et al 2005, Rezvani et al 2007). 
Other processes that may contribute to nAChR upregulation include increased 
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nAChR trafficking to the cell surface (Darsow et al 2005) and increased nAChR 
subunit maturation and assemblage (Harkness & Millar 2002, Sallette et al 2005). 
Another critical aspect of nicotine-induced neuroadaptation is that upregulation of 
nAChRs occur in a subtype-specific manner, and each of these receptor subtypes 
are differentially expressed across brain regions. These regional dissimilarities in 
nAChR subtype expression and upregulation following chronic nicotine use may 
influence nicotine-induced neuroadaptation in various neural circuitry (De Biasi & 
Dani 2011). Evidence of such diversity in nAChR subtype expression and 
upregulation have been shown in the mesolimbic dopamine reward circuit. For 
example, striatal dopaminergic neurons primarily express five nAChR subtypes – 
α4α5β2, α4α6β2β3, α4β2, α6β2β3, α6β2; however, the expression density of the 
α4* subtypes is higher compared to the α6* subtypes across the striatum (Grady 
et al 2007). α4β2 nAChR is one of the most abundant and widely distributed 
nAChR subtypes in the brain. It is well expressed by both dopaminergic and non-
dopaminergic neurons in the striatum, but a subpopulation also containing α5 
(α4α5β2 subtype) is only expressed on the striatal dopaminergic terminals (Zoli et 
al 2002). Amongst many other nAChR subtypes, α4β2 nAChRs are the most 
implicated in nicotine-induced neuroadaptation and nicotine dependency 
(Benowitz 2008b). For example, evidence from previous studies examining 
functional upregulation of nAChR, a direct and important nicotine-induced 
neuroadaptation, have demonstrated that α4β2 subtype is the most upregulated in 
the brain compared to other nAChR subtypes (Buisson & Bertrand 2002). Another 
study also reported that chronic nicotine administration selectively increases the 
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expression of α4β2 nAChR on dopaminergic terminals in the striatum, and more 
importantly, this receptor remains functional in contrast to the general idea that 
upregulated receptors are desensitized (Xiao et al 2009). Further studies also 
implicated selective upregulation of α4β2 nAChR in presynaptic modulation of 
dopamine release in the striatum (Sharples et al 2000), even though, another study 
showed that α6β2β3 nAChR can partly contribute to this nAChR-related function 
in the striatum (Cao et al 2005). However, it is noteworthy to mention that there is 
ambiguity in findings related to nicotine-induced upregulation of α6β2 receptors. 
While a study that utilized mammalian cell lines showed that co-expression of  β3-
subunits increase in α6β2 and α6β4 receptor levels (Tumkosit et al 2006), another 
study in brain tissue showed that striatal α6-containing receptors without β3 are 
downregulated by nicotine and those containing β3 are unaltered. 
 
1.3    MAJOR NEURAL PATHWAYS INVOLVED IN NICOTINE DEPENDENCE 
Following nAChR activation in the brain, nicotine engages multiple 
neurotransmitter systems, usurping their neural elements to precipitate its effects. 
One of these neurotransmitter systems is the brain’s dopaminergic system, which 
is the primary neural framework mediating the reinforcing and rewarding effects of 
nicotine. Other key neurotransmitter systems are the major excitatory and 
inhibitory neurotransmitters in the brain, namely glutamate and GABA, 
respectively. Both neurotransmitters can modulate nicotine’s reinforcing and 
rewarding effect by enhancing (glutamate) or inhibiting (GABA) dopamine release 
in the mesocorticolimbic circuits. Excitatory and inhibitory control of nicotine-
 
 8 
induced dopamine effects is possible because of complex interactions existing 
between mesocorticolimbic dopaminergic neurons and the glutamatergic inputs 
from the cortical and limbic nuclei, and GABAergic inputs from the local 
interneurons as well as interneurons from distant nuclei (D'Souza & Markou 2013, 
Yager et al 2015). Studies investigating how these interactions impact nicotine 
dependence have shown that inhibition of glutamatergic neurotransmission or 
stimulation of GABAergic neurotransmission attenuates nicotine intake and 
nicotine-seeking behavior in rodents (D'Souza & Markou 2013).  
 
Mesocorticolimbic pathway 
The mesocorticolimbic pathway, also known as the reward pathway, is the critical 
neural pathway for reinforcing rewarding behaviors, including those behaviors 
underlying drug addiction. All drugs of abuse including nicotine are believed to 
enhance the effect of dopaminergic function in the mesocorticolimbic pathway, 
particularly, at the dopaminergic nerve terminals in the nucleus accumbens (NAc) 
– a key neural substrate of motivation and reward (D'Souza & Markou 2011, Dani 
& De Biasi 2013, Hyman et al 2006, Volkow & Li 2004). Apart from the NAc, other 
major brain structures in the dopaminergic pathway includes ventral tegmental 
area (VTA), prefrontal cortex (PFC), substantia nigra (SNr), and caudate-putamen 
(CPu). Although dopaminergic neurons originate from both SNr and VTA, these 
structures project to different brain regions. Dopaminergic axons from the SNr 
project to the caudate putamen in the nigrostriatal pathway, while the axons of 
dopaminergic neurons in the VTA project primarily to the NAc and PFC in the 
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mesocorticolimbic circuit (Figure 1). In drug addiction, the role of dopaminergic 
axon projection from SNr to its targets is not really well-defined (Dani & De Biasi 
2013), even though it is a well-described motor circuit. However, VTA 
dopaminergic projections to the NAc have been identified as the principal neural  
 
 
Figure 1.1: Simplified mesocorticolimbic and nigrostriatal pathways 
framework shaping reward-related behaviors. In fact, in the context of drug 
addiction, this pathway is the most crucial neural substrate for acute rewarding 
effects of all drugs of abuse, regardless of their dissimilar mechanism of action 
(Markou 2008, Volkow & Li 2004, Volkow & Morales 2015). Nicotine’s activation of 
the VTA-NAc pathway can occur either directly via stimulation of nAChRs on VTA-
NAc dopaminergic terminals in the VTA or indirectly through stimulation of nAChRs 
on glutamatergic nerve terminals innervating dopaminergic neurons in the VTA 
(D'Souza & Markou 2011). Regardless, both activation pathways lead to dopamine 





The striatum is a critical component of the mesocorticolimbic system, and it is a 
heterogeneous structure with two distinct subregions – the dorsal striatum (mainly 
the CPu) and the ventral striatum (mainly the NAc). These striatal subregions are 
the main input structures in the mesocorticolimbic pathway, functioning as hubs 
coordinating various neuronal activities. Major inputs received by these subregions 
includes the dopaminergic inputs from VTA and SNr, and the glutamatergic 
projections from the PFC. Both inputs physically interact at different sites on the 
dendritic spines of striatal GABAergic medium spiny neurons (MSN), which 
account for ~95% of the striatal neuronal population (Yager et al 2015). This 
complex interaction controls MSN activity within the striatum (Yager et al 2015). 
Striatal MSNs relay information to neighboring structures such as SNr via the direct 
pathway (dMSNs) and to the subthalamic nuclei (STN) via the indirect pathway 
(iMSNs). While these striatal output pathways are found in both the CPu and NAc, 
their target structures are different. In the NAc, the iMSNs, which primarily express 
dopamine D2 receptors, specifically project to the ventral pallidum (VP), and the 
dMSNs, which generally express dopamine D1 receptors, project mainly to the 
VTA and SNr. In contrast, iMSNs in the CPu project largely to the globus pallidus 
external (GPe) and STN, while its dMSNs extend particularly to the globus pallidus 
internal (GPi) and SNr. Of note, these striatal output pathways are not absolutely 
separated as there can still be overlapping projections such as the extension of 
dMSNs axon collaterals to the GPe/VP (Fujiyama et al 2011). In drug addiction, 
the CPu and the NAc have differing functional roles, even though in a simplistic 
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view they both receive similar neuronal inputs. For instance, as drug addiction 
progresses from occasional recreational use to compulsive use, drug-seeking 
behavior is thought to switch from reward-driven to habit-driven – drug-seeking 
behaviors that are controlled by NAc and CPu respectively (Clarke & Adermark 
2015). This differential role is supported by several studies such as that which 
previously demonstrated dissimilar dopamine signaling in the CPu and NAc 
following chronic nicotine use (Zhang et al 2009). Overall, these differences in the 
neuroanatomical organization of caudate-putamen and nucleus accumbal 
afferents and efferents contribute to their differential roles in motivation and motor 
function. 
 
1.4    ROLE OF WITHDRAWAL SYMPTOMS IN NICOTINE DEPENDENCE 
Nicotine withdrawal symptoms manifest a few hours after discontinuation of 
nicotine use, and the collection of these negative symptoms during abstinence 
from nicotine is the major determinant preventing smokers from successful quitting 
(McLaughlin et al 2015). Symptoms of nicotine withdrawal encompass affective, 
cognitive, and somatic domains.  Affective symptoms include anxiety, depression, 
irritability, anhedonia, hyperalgesia, and dysphoria, while memory impairment and 
difficulty concentrating are cognitive manifestations (McLaughlin et al 2015).  
Together, the biological basis of nicotine addiction can be regarded as a mix of 
positive reinforcement, such as mood enhancement, and avoidance of negative 




Anxiety-Related Withdrawal Phenotypes 
Affective nicotine withdrawal symptoms are critical determinants of smoking 
motivation (Leventhal et al 2013) and individuals who quit smoking often 
experience symptoms of anxiety. A randomized placebo-controlled clinical trial has 
shown that anxiety is a discrete, quantifiable affective manifestation of nicotine 
withdrawal, which directly impacts relapse to smoking (Piper et al 2011). To 
advance the current understanding of anxiety-like behaviors during withdrawal 
from nicotine, better insight into the neurocircuitry and neuroadaptations 
associated with withdrawal-induced anxiety is critical.  
         There is mounting evidence implicating the mesolimbic dopamine signaling 
in the neurobiology of mood and anxiety (Russo & Nestler 2013). One of the critical 
neural substrates of anxiety-like behaviors in the mesolimbic pathway is the 
nucleus accumbens. The nucleus accumbens plays an important role in anxiety 
disorders (Levita et al 2012, Russo & Nestler 2013) and nicotine withdrawal-related 
anxiety (Morud et al 2018, Torres et al 2015). Besides the nucleus accumbens, 
studies have also demonstrated the role of ventral hippocampus (Fisher et al 2017) 
and medial habenula (McLaughlin et al 2015, Pang et al 2016) in nicotine 
withdrawal-related anxiety. This indicates that withdrawal-related anxiety may be 
a function of molecular disruptions or neuroadaptive changes in multiple 
neuroanatomical structures or neurocircuitry. Withdrawal from nicotine during 
smoking cessation alters nAChR number or function in widely distributed neural 
circuits such as the mesocorticolimbic circuitry, and these changes have been 
shown to coincide with anxiety (Grady et al 2007, Yohn et al 2014). Studies have 
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also shown that withdrawal-induced anxiety can be influenced by the subunit 
composition of nAChRs. For instance, α6- and β2-containing nAChR subunits are 
required for increased anxiety during nicotine withdrawal (Jackson et al 2008, 
Jackson et al 2009), while α5 and α7 may not be necessary (Jackson et al 2008).  
         Generally, quantification of anxiety and other affective symptoms in rodents 
are relatively subtler than somatic signs, which are the most often evaluated 
withdrawal symptoms in rodent models. One of the well-validated behavioral 
paradigms commonly used in assessing anxiety-like behavior in chronic nicotine 
studies is the novelty-induced hypophagia (NIH), which is very sensitive to acute 
treatment with anxiolytic drugs. The NIH test is a hyponeophagia-based paradigm 
that quantifies anxiety based on animals’ latency to feed in a novel environment 
(Dulawa & Hen 2005, Fisher et al 2017). Open field (Cohen et al 2009) and marble-
burying (Turner et al 2014, Turner et al 2013b) tests are also frequently used in 
evaluating anxiogenic behavior in mice. Both behavioral paradigms, similar to NIH, 
are well-validated models with high predictive validity for anxiolytics and 
antidepressants. 
 
Cognition-Related WD Phenotypes 
Cognition is a brain-related function that is negatively impacted by nicotine 
withdrawal. Impaired neurocognitive control during nicotine withdrawal often 
manifest as inability to change nicotine-seeking and -taking responses that are 
provoked by stimuli related to previous nicotine’s rewarding effects. This symptom 
is basically characterized with attention deficits and memory impairment, and 
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together with affective nicotine withdrawal symptoms, are thought to predict 
relapse (Ashare et al 2014). Previous studies in mice and humans have shown 
that re-exposure to nicotine can reverse nicotine withdrawal-related cognitive 
deficits (Davis et al 2005, Ernst et al 2001, Patterson et al 2009, Portugal & Gould 
2007).  
An important neural substrate of cognitive control processes is the 
frontostriatal circuits, which include discrete regions of the prefrontal cortex and 
the striatum. The frontostriatal circuits are critical neural pathways for executive 
functions, which include adaptation to changes, decision making, working memory, 
planning and organization. These cognitive functions are normally disrupted during 
nicotine withdrawal (Parikh et al 2016). However, while the neural mechanism 
altered during nicotine withdrawal is still not completely understood, changes in 
nAChR numbers and function may contribute to the disruption and impairment of 
cognitive control processes during nicotine withdrawal. For example, studies have 
indicated that β2-containing nAChRs, including α4β2 receptors, mediate nicotine 
withdrawal-related deficits in contextual fear conditioning (Gould et al 2012, 
Portugal et al 2008), which is a form of associative learning. Evaluation of 
associative learning can be performed in rodents by utilizing contextual and cued 
fear conditioning test, which are behavioral models that assess the ability of a mice 
to learn and recall an association between environmental cues (context such as a 
location or stimulus such as a tone) and aversive experiences (aversive stimuli 
such as an electric shock) (Ashare et al 2014). Another relevant behavioral 
paradigm of cognition is the novel object recognition test. This test is frequently 
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utilized in evaluating memory-related cognitive deficits. It assesses rodents based 
on their tendency to spend more time exploring a novel object rather than a familiar 
one. One more cognitive control process that may be impaired during nicotine 
withdrawal is attention. Attention-related cognitive deficits are evaluated in rodents 
by performing operant signal detection task (Ashare et al 2014). 
 
1.5    NOVEL TARGETS FOR SMOKING CESSATION: NON-NEURONAL 
CELLS IN NICOTINE DEPENDENCE 
Over the years, exploration of neuronal targets has been the primary research 
focus of nicotine dependency; however, it is becoming evident that non-neuronal 
cell-types such as astrocytes and microglia, are actively involved in the functional 
organization of the brain (Allen & Barres 2009, Cerbai et al 2012). Both neuronal 
and non-neuronal cell-types constantly interact in their local microenvironment to 
maintain the integrity of brain structures (Allen & Barres 2009). However, impaired 
interplay amongst these brain cell-types as a consequence of chronic exposure to 




Astrocytes are the most abundant glial cells in the mammalian brain. They are 
morphologically complex cells with numerous processes, which are typically 
bushy. However, with their finest branching processes, they physically interact with 
blood vessels, other glial cells, and synapses (main elements are presynaptic and 
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postsynaptic terminals) in a structure known as the tripartite synapses. It is 
considered that finely branching processes from a single astrocyte physically 
interact with several hundreds of multiple neuronal dendrites and wraps over 
100,000 synapses in the hippocampus or cortex (Sofroniew & Vinters 2010). 
Similar studies in the hippocampus demonstrated that ~57% of synapses are in 
physical contact with astrocytes (Harada et al 2015).  
Furthermore, astrocytes can exhibit regional heterogeneity with respect to 
their ratio to that of neurons (astrocyte-to-neuron ratio). They exist in high density 
in some neural circuits such as the cerebral cortex, where the astrocyte-to-neuron 
ratio is high, and low density in some regions like the cerebellum, where the 
astrocyte-to-neuron ratio is low (Khakh & Sofroniew 2015). The functional 
relevance of this regional diversity is still unclear.  
         The role of astrocytes in the brain were once thought to be limited to 
metabolic and trophic support for neurons, ionic and pH homeostasis, and the 
formation and maintenance of the blood-brain barrier; however, it is now becoming 
more evident that astrocytes are active participants in the modulation of neuronal 
activity in the brain. Drugs of abuse such as nicotine can disrupt the interplay 
between astrocyte and neuron in the brain by direct or indirect modulation. For 
direct modulation, nicotine can directly bind to nAChRs on astrocytes. Studies 
have demonstrated that astrocytes express α3, α4, α7, β3, β4 subunits of nAChR, 
with the α7 subunit being the most predominantly expressed (Gotti & Clementi 
2004). In addition, α3β4 and α4β2 nAChR expression have also been reported in 
the soma and processes of astrocytes (Graham et al 2003). Several studies have 
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linked astrocyte nAChRs, especially the α7-subtype, to neuroinflammatory 
processes in Alzheimer’s (Teaktong et al 2003) and Parkinson’s disease (Liu et al 
2015, Quik et al 2009), both neurodegenerative disorders in which nicotine use 
has been reported as beneficial (Newhouse et al 2012, Villafane et al 2007). 
Nicotine’s interaction with astrocyte nAChRs may further result in an increase in 
the intracellular Ca2+ concentration (Sharma & Vijayaraghavan 2001) and 
subsequent release of gliotransmitters. Gliotransmitters can alter synaptic activity 
and function in neural circuits. For example, a study examining nicotine’s 
modulation of neuron-glial interaction showed that the release of astrocyte D-
serine following nicotine stimulation is necessary for nicotine’s enhancement of 
synaptic transmission and long-term memory (Lopez-Hidalgo et al 2012). 
However, for indirect modulation, nicotine can regulate astrocyte activity and 
function by releasing neuromodulators such as dopamine. For instance, a recently 
published study demonstrated that extracellular dopamine can modulate astrocyte 
morphology and function (Galloway et al 2018).   
         One other mechanism through which astrocytes actively participate in 
synaptic transmission is the clearance of small molecule neurotransmitters, such 
as glutamate. Excitatory amino acid transporter (EAAT2), which is primarily 
expressed on astrocytes, plays a major role in glutamate clearance – responsible 
for >90% glutamate uptake (Kim et al 2011). Elevated glutamate levels in the brain 
underlies many neurodegenerative and neurological disorders, and dysfunctional 
EAAT2 have been linked with the initiation of a number of these brain disorders 
(Kim et al 2011). Similarly, in nicotine addiction studies, rats undergoing withdrawal 
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from chronic nicotine were found to have decreased EAAT2 expression 
(Knackstedt et al 2009), indicating a role for this astrocyte glutamate transporter in 
nicotine seeking behaviors (Spencer & Kalivas 2017).  Together, astrocytes may 




Microglia are the resident innate immune cells in the brain and account for ~10% 
of the CNS cell population in the healthy brain (Salter & Stevens 2017). In terms 
of their developmental origin and functions, microglia are a unique population 
among the other brain cell-types. Like peripheral myeloid cells, microglia are 
derived from mesoderm lineage, and are unlike other brain cell-types, which are 
derived from neuroectodermal progenitors. Recent lineage-tracing studies 
provided additional characterization of microglia origin, showing that they are 
derived from the yolk-sac progenitors – an embryonic origin distinct from that of 
the peripheral myeloid populations (Madore et al 2017). 
         Microglia are highly branched, dynamic cells with relatively rapid movement 
compared to other brain cell-types. These features, in addition to their fine motile 
processes, allows them to constantly scan the brain parenchyma to maintain 
homeostasis. Further, as CNS surveillance elements, microglia can sense and 
respond accordingly to extracellular signals. Based on the signal pattern, microglia 
can assume diverse morphological phenotypes that have been previously 
classified into M1 microglia – the pro-inflammatory activation phenotype, or M2 
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microglia - the anti-inflammatory activation phenotype. This simplistic 
characterization of microglia activation phenotypes is based on the presence of 
particular cell surface molecules and the expression of specific sets of cytokines 
(Butovsky & Weiner 2018). For example, M1 microglia were associated with 
factors such as tumor necrosis factor alpha (Tnfα), interleukin-1-beta (Il1β), and 
reactive oxygen species (ROS), while M2 microglia were typified by interleukin-10 
(Il10) and transforming growth factor beta (TGF-β) (Butovsky & Weiner 2018, Tang 
& Le 2016). However, evidence from more recent studies that re-characterize 
microglial diversity (Butovsky et al 2014) have shown that the simplistic view of 
microglial phenotype does not sufficiently represent the intricate physiology of 
microglial cells (Ransohoff 2016). In addition to the phenotypic complexities of 
microglia, they are also largely heterogeneous across diverse neural circuits and 
brain regions. For example, a recent study that examined microglial phenotypes 
among a group of subcortical nuclei revealed that microglia across the basal 
ganglia are very diverse in terms of their density and morphology, metabolic and 
activational state, and transcriptome (De Biase et al 2017). This implicates local 
cues as a critical mediator of microglia phenotype across neural circuit (McCarthy 
2017). Further, regional microglial heterogeneity may also reflect diverse 
functional phenotypes required for the integrity of the various CNS environment in 
which the microglia lives. 
         Microglia were once considered only as support cells in the brain (Streit 
2002), but recent evidences suggest they are active players in brain function and 
dysfunction (Salter & Stevens 2017). In addition to their immune functions, 
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microglia are critical elements in synaptic remodeling and plasticity (Miyamoto et 
al 2016, Torres et al 2016), placing them as a potential  participant in 
neuroplasticity underlying drug addiction. Similar to astrocytes, nicotine and many 
other drugs of abuse can directly modulate microglial morphology and function via 
interaction with nAChR on microglia. However, to date, α7-nAChR is the only 
nAChR subtype reportedly found on microglia. It is noteworthy to mention that most 
studies, except one (Shytle et al 2004), that have reported α7-nAChR expression 
on microglia were done in immortalized microglial cell lines or primary microglial 
cultures (De Simone et al 2005, King et al 2017, Mencel et al 2013, Shytle et al 
2004, Suzuki et al 2006), which both have their own drawbacks (Stansley et al 
2012). Microglia may also be indirectly modulated by nicotine via neurotransmitter 
release. Human induced pluripotent stem cells, human postmortem tissues, or 
rodents may be more suitable models for investigating nicotine’s interaction with 
microglia. At the present time, nicotine’s modulatory mechanism of microglial 
function and how these may impact behavior are still unclear. However, a recent 
study demonstrated that microglial activation and impaired neurogenesis are 
associated with cognitive deficits during nicotine withdrawal (Saravia et al 2019). 
While microglia may actively contribute to nicotine dependency, research studies 
investigating the role of microglia in nicotine dependence is still in the early stages.  
 
1.6    CONCLUSION 
This chapter extensively covered acute and chronic effects of nicotine, as well as 
the neural substrate of motivation and reward-related behaviors. We discussed 
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functional upregulation of nAChRs, a nicotine-induced neuroadaptation, and 
highlighted its potential role in nicotine withdrawal-related behaviors. Finally, rather 
than the conventional research focus on neuronal targets, we explored the 
possibilities of non-neuronal cell types as novel targets in the development of new 
smoking cessation aids. 
 
Future of pharmacotherapy development and potential role of glial targets 
There are presently three FDA-approved first-line smoking cessation medications: 
Nicotine Replacement Therapy (NRT), bupropion, and varenicline (Jiloha 2014, 
Prochaska & Benowitz 2016). However, despite years of innovation and 
advancement in the development of smoking cessation medications, a large 
population of smokers attempting to quit still fail. This may be largely attributable 
to the inability of current smoking cessation therapies to address some critical 
aspects of nicotine dependency. For instance, all the three FDA-approved smoking 
cessation medications were developed to mechanistically target neuronal 
nAChRs, neglecting the possible contributions of targets on non-neuronal cells like 
astrocytes and microglia.  
         To advance nicotine addiction research, novel studies exploring astrocytes 
and microglia function in nicotine dependence should be prioritized. Long-term, 
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2.1    ABSTRACT 
Microglia are active participants in the pathogenesis of several neurodegenerative 
diseases; however, their role in nicotine withdrawal-related anxiety, which directly 
impacts relapse to smoking in humans, is unknown. This study outlines a series of 
novel findings that demonstrate alteration in microglial morphology and function 
underlies nicotine withdrawal-related anxiety. Here, we examined the striatum – a 
key brain region implicated in reward-related processes and affective behavioral 
symptoms such as anxiety. First, we show that both chronic nicotine and 
withdrawal provoke microglial activation in the nucleus accumbens but not the 
caudate putamen. Further, in the nucleus accumbens, nicotine withdrawal induces 
proinflammatory responses, which was muted during chronic nicotine treatment. 
Similarly, microglia-related NADPH oxidase 2 (Nox2) induction and aberrant 
reactive oxygen species (ROS) production occurred during nicotine withdrawal, 
but not during chronic nicotine treatment, in the nucleus accumbens. We utilized a 
well-described antioxidant, N-acetylcysteine (NAC), and show that aberrant ROS 
production significantly contributes to nicotine withdrawal-related anxiety. Further, 
depletion of microglia with PLX5622 attenuates both nucleus accumbal Nox2 and 
ROS, as well as nicotine withdrawal-related anxiety. More directly, our microglia 
depletion studies reveal a strong link between microglial function and nicotine 
withdrawal-related anxiety. Taken together, we provide the first evidence that 
nicotine withdrawal alters microglial morphology and function, which underlies 
nicotine withdrawal-related anxiety. Long-term, further investigation into 
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modulators of microglial function during nicotine withdrawal represents an 
untapped therapeutic avenue for smoking cessation.  
 
2.2    INTRODUCTION  
While smoking cessation significantly reduces the risk of smoking-related diseases 
such as cancer, stroke, respiratory and heart diseases (Babizhayev 2014, Samet 
2013), nearly 80% of smokers attempting to quit still fail (Polosa & Benowitz 2011). 
Currently, tobacco smoking is the leading cause of preventable morbidity and 
mortality globally (World Health Organization 2012), which underscores the need 
for better therapeutics for nicotine dependence. Pharmacotherapies for nicotine 
dependence have largely targeted nicotinic acetylcholine receptors (nAChRs), as 
activation of these receptors by nicotine mediates the rewarding effects of tobacco 
(Coe et al 2005, Polosa & Benowitz 2011, Rollema et al 2007, Xiao et al 2006). 
However, the molecular mechanism underlying vulnerability to smoking relapse is 
multifaceted (Polosa & Benowitz 2011). One avenue for development of new 
therapeutics is reassessing the symptomology of individuals undergoing nicotine 
withdrawal.  For example, patients with smoking-related disease, such as chronic 
obstructive pulmonary disease, often present with increased cellular oxidative 
stress levels. These observed effects may be the result of inhaled oxidants present 
in cigarette smoke (Babizhayev 2014). However, individuals attempting to quit 
smoking may also lose nicotine’s neuroprotective effects (Barreto et al 2014, Lu et 
al 2017, Ross & Petrovitch 2001, Tariq et al 2005) . For example, clinical studies 
have shown nicotine transdermal patches to be neuroprotective in 
 
 25 
neurodegenerative diseases such as Alzheimer’s (Newhouse et al 2012, Wilson 
et al 1995) and Parkinson’s (Villafane et al 2007), two diseases with extensive ties 
to inflammatory responses (Amor et al 2010). This would suggest that smoking 
cessation, while reducing the inhaled level of oxidants, may also remove the 
potential anti-inflammatory benefits of nicotine in the brain.  
         Microglia are highly specialized resident immune cells, which act as the 
brain’s homeostatic sensor. Their constant surveillance of the brain 
microenvironment enables them to detect and respond to homeostatic 
perturbations by altering their own morphology in diverse ways depending on the 
type of stimuli they sense. Such changes in microglial morphology are more 
indicative of an imbalance in CNS homeostasis following an insult or injury and not 
a particular activation phenotype (M1 pro-inflammatory phenotype or M2 anti-
inflammatory phenotype) as initially conceptualized (Ransohoff 2016, Salter & 
Stevens 2017). Furthermore, studies have described microglia as critical elements 
in synaptic remodeling (Miyamoto et al 2016, Weinhard et al 2018), as well as 
learning and memory (Torres et al 2016) – processes prominently affected during 
development of drug dependence (Kutlu & Gould 2016, Torregrossa et al 2011). 
In addition to neuroplasticity-related events, microglia actively participate in 
reactive oxygen species (ROS) generation (Lull & Block 2010). While ROS are key 
intracellular signaling molecules for normal cell function, they can become toxic 
when there is a chronic imbalance between oxidant and antioxidant signaling 
within the cell, termed oxidative stress (Schieber & Chandel 2014). Since neurons 
are particularly susceptible to oxidative insult, aberrant ROS production and 
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signaling can significantly impact brain function and behavior (Li et al 2016, Seo et 
al 2012).  For example, correlative studies examining patients diagnosed with 
Parkinson’s disease found a strong relationship between oxidative stress and 
striatal neurodegeneration (Ikawa et al 2011). However, while the striatal 
neurocircuit is a major site for neuroadaptive events underlying addictive 
processes (Yager et al 2015), the effects of nicotine withdrawal on microglia 
phenotype and related ROS homeostasis in this region are unknown. 
         The striatum is a heterogeneous structure with two distinct sub-regions – the 
caudate-putamen, which contributes to motor functions and movement, and the 
nucleus accumbens, which is key for motivation and reward processes (Yager et 
al 2015). Our lab (Fisher et al 2017, Turner et al 2014) and others (Lee et al 2015, 
Manhaes et al 2008) have shown that anxiety is a discrete, quantifiable symptom 
of nicotine withdrawal, which has been shown to directly impact smoking relapse 
in humans (Piper et al 2011). Previous studies in humans have demonstrated the 
contribution of mesolimbic dopamine signaling in the nucleus accumbens to 
anxiety-related processes (Kim et al 2008, Levita et al 2012, Lorberbaum et al 
2004). Further, chronic stress studies have reported increased levels of oxidative 
stress markers in other parts of the mesolimbic circuitry to coincide with increased 
anxiety-like behavior (Patki et al 2013, Salim et al 2010). However, it is unknown 
whether nicotine withdrawal elicits changes in microglial morphology and function, 
and whether these changes directly impact anxiety. Our studies are the first to 
report nucleus accumbens-specific alterations in microglial morphology and ROS 
homeostasis.  Further, we demonstrate compelling evidence that these microglia-
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related effects are critical mediators of anxiety-like behaviors in mice during 
nicotine withdrawal. 
 
2.3    MATERIALS AND METHODS 
Animals 
For the majority of the experiments described, male B6/129SF1 and B6/129PF1 
mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA; 8 -10 
weeks of age; 20 - 31 g). Magnetic activated cell sorting (MACS) experiments 
examining cell-type specific mRNA expression utilized male B6/129 mice bred in 
house (8 -10 weeks of age; 20 - 31 g). All mice were housed in groups of two to 
four, and randomly assigned to treatment conditions. They were maintained on a 
12-h light/dark cycle with food and water ad libitum in accordance to the University 
of South Carolina Animal Care and Use Committee. All behavioral testing sessions 
were conducted between the 0900 and 1300 hours. 
 
Osmotic drug delivery and treatment  
(-)-Nicotine tartrate (MP Biomedicals, Solon, OH, USA) was dissolved in sterile 
0.9% sodium chloride solution, and then infused subcutaneously via osmotic 
minipumps (Alzet model 2002; DURECT Corporation, Cupertino, CA, USA) at a 
dose of 18 mg/kg/day for 15 days. The control group was infused with saline for 
the same period of time. Chronic treatment with nicotine at this dose yields a 
plasma level of approximately 0.3 μM in mice (reported as nicotine free base 
molecular weight), a concentration comparable to that observed in human smokers 
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consuming an average of 17 cigarettes a day (plasma levels between 0.06 - 0.31 
μM) (Matta et al 2007). Prior to the start of surgery, mice were anesthetized with 
isoflurane/ oxygen mixture (1 - 3%), and minipumps were inserted using aseptic 
techniques. Surgical wounds were closed with 7 mm stainless steel wound clips 
(Reflex, Cellpoint Scientific, Gaithersburg, MD, USA), after which mice were left to 
recover on the recovery pad before they were returned to their individual cages. 
After 14 days of chronic administration of either saline or nicotine via osmotic 
minipumps, mice earmarked for withdrawal from chronic nicotine and their 
assigned saline controls were subjected to spontaneous withdrawal by the removal 
of their osmotic minipumps using a similar aseptic surgical approach as above. 
Tissues were collected from mice after 48 h withdrawal.   
 
Injection drug delivery and treatment  
N-acetylcysteine (NAC) (A7250, Sigma-Aldrich, St Louis, MO, USA) was dissolved 
in sterile 0.9% sodium chloride solution, adjusted to pH 7, and administered 
intraperitoneally (IP) at a dose of 150 mg/kg per day for 4 days (24 h prior to 
withdrawal, and each morning for the next 3 days). The administered NAC dose 
was selected based on previously published studies (Cao et al 2012, Victor et al 
2003). Post-withdrawal NAC injections were given 30 minutes before behavioral 
testing. Mice not receiving NAC were injected with vehicle (sterile 0.9% sodium 





Microglia depletion via chow treatment  
Plexxikon Inc. (Berkeley, CA) provided colony stimulating factor-1 receptor 
(CSF1R) inhibitor, PLX5622, which was formulated in AIN-76A chow at a dose of 
1200 ppm by Research Diets (New Brunswick, NJ). Control chow was also 
provided. Male B6/129SF1 mice (8 weeks old) received either control chow or 
PLX5622 chow for 7 days prior to withdrawal and all through 48 h withdrawal 
period. 
 
Open field test and locomotor activity 
The open field test is an anxiety-related behavioral model, which also allows 
simultaneous assay of overall locomotor activity levels in mice. All mice were 
tested in this model at 24 h withdrawal timepoint. Test chambers were wiped with 
70% ethanol in between tests to remove any scent cues left by the previous mouse. 
The ethanol was allowed to dry completely before each testing, and every testing 
session lasted for 15 minutes. For the analysis, Top Scan (Clever Sys Inc., Reston, 
Virginia, USA) software was utilized to track and evaluate mouse movement. Prior 
to tracking analysis for each mouse, a background profile was generated, and the 
testing chamber was calibrated in arena design mode according to manufacturer’s 
instructions. Software output for each individual test includes total distance moved 
(in mm) and the time spent in the center (in %). These data were then normalized 






The marble-burying test is an animal behavioral model of anxiety that has high 
predictive value in detecting anxiolytic drugs. All mice were tested in this model at 
48 h withdrawal timepoint. Mice were placed individually in small cages (29.0 cm 
x 17.5 cm), in which 20 marbles had been equally distributed on top of mouse 
bedding (5 cm deep). A lid was placed on top of the cage to prevent the mouse 
from jumping out of the cage during the test. Mice were left undisturbed for 15 
minutes, after which the number of buried marbles (those covered by bedding 
three-quarters or more) was counted by an observer blinded to experimental 
conditions.  
 
Quantitative PCR  
Quantitative reverse transcriptase PCR was performed as previously described 
(Cleck et al 2008) on caudate putamen or nucleus accumbens samples across all 
treatment groups. Briefly, RNA was isolated using the RNeasy Mini Kit (Qiagen, 
Venlo, The Netherlands), and qPCR reactions were assembled using synthesized 
complementary DNA, Thermo Scientific Maxima SYBR Green master mix along 
with 100 nM primers (Integrated DNA Technologies, Inc., Coralville, Iowa, USA) 
diluted to 4.3 nM final concentration. The mRNA levels were determined using the 
2 −ΔΔCT method (Livak & Schmittgen 2001) and target genes were normalized to 
the housekeeping gene, hypoxanthine phosphoribosyltransferase (HPRT). All 
gene expression values were normalized to their respective saline controls. Primer 
sequences are available upon request. 
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Western blot  
Protein analysis was performed as described previously (Portugal et al 2012) on 
nucleus accumbens samples of all treatment groups. Briefly, 20 μg of protein were 
resolved in Any KD precast polyacrylamide gel (Bio-Rad Laboratories Inc., 
Hercules, CA, USA) and transferred to nitrocellulose membranes. Membranes 
were incubated with LI-COR blocking buffer (LI-COR, Lincoln, NE, USA) for 1 h at 
room temperature before reacting overnight at 4 oC with primary antibodies (Nox2 
(1:1000, ab129068, Abcam Biotechnology, Cambridge, UK) and GAPDH (1:1000, 
sc-32233, Santa Cruz Biotechnology, Santa Cruz, CA, USA)). After washing in 
phosphate buffered saline-Tween-20, the blots were incubated in fluorescent 
secondary antibodies (1:20000, LI-COR) in LI-COR blocking buffer for 1 h at room 
temperature. Membranes were then washed, and immunolabeling detection and 
densitometry measurements were performed using the LICOR Odyssey System 
(LI-COR). Ratios of Nox2 (60 kD band) to GAPDH densities were calculated for 
each sample and analyzed across conditions. 
 
Protein carbonylation assay 
Protein carbonyl derivatives were determined in caudate putamen and nucleus 
accumbens samples of all treatment groups using OxiSelect Protein Carbonyl 
Immunoblot Kit (Cell Biolabs, Inc., San Diego, CA, USA) following the 
manufacturers details. Briefly, 20 μg of protein were resolved in Any KD mini-
protean precast polyacrylamide gel (Bio-Rad Laboratories Inc., Hercules, CA, 
USA) and transferred to nitrocellulose membranes. Membranes were processed 
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for 2,4-dinitrophenylhydrazine (DNPH) derivatization by equilibrating them in Tris 
buffered saline (TBS) containing 20% methanol, followed by washes in 2 N HCL, 
incubation in 1X DNPH, and final washes in 2 N HCL and 50% methanol. DNPH-
treated membranes were then incubated with LI-COR blocking buffer (LI-COR, 
Lincoln, NE, USA) for 1 h at room temperature before reacting overnight at 4 oC 
with primary antibodies (Anti-DNP (1:1000, Cell Biolabs, Inc.) and GAPDH 
(1:1000, sc-32233, Santa Cruz Biotechnology, Santa Cruz, CA, USA)). After 
washing in Tris buffered saline-Tween-20 (TBST), the blots were incubated with 
fluorescent secondary antibodies (1:20000, LI-COR) in LI-COR blocking buffer for 
1 h at room temperature. Membranes were then washed, and immunolabeling 
detection and densitometry measurements were performed using the LICOR 
Odyssey System (LI-COR). DNP signals were normalized to GAPDH densities for 
each sample. 
 
Immunohistochemistry and microglia morphological analysis  
One brain hemisphere from each mouse was collected and fixed overnight in 4% 
paraformaldehyde in PBS. Fixed brains were cryoprotected by leaving them 
overnight in 15% sucrose, and then in 30% sucrose for 48 h. Cryoprotected brain 
hemispheres were sectioned through the striatum at 45 microns and processed for 
IBA1 immunohistochemistry. Briefly, cryosections were incubated in a rabbit anti-
IBA1 primary antibody overnight (1: 1,000; Wako Catalog No. 019-19741), 
followed by a 2-h incubation in a goat anti-rabbit secondary (1:500, Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA). The signal was amplified 
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with the avidin biotin complex (ABC; Vector Labs) method (1:500) and visualized 
with Vector ® VIP peroxidase substrate to yield a purple reaction product. Images 
were generated at 200X magnification using Leica DMI 3000B microscope (Leica 
Microsystems Inc., Buffalo Groove, IL, USA) fitted with Leica DFC 290HD digital 
camera. Leica LAS core software was used for image acquisition. Morphological 
analyses were conducted with National Institutes of Health ImageJ software. For 
IBA1-positive cell count/ density, cell area, and cell perimeter measurements, 
images were converted from RGB to 16-bit format before applying a threshold and 
subsequent binary mask. Objects within each masked image were then scanned, 
counted, and measured using the “Analyze Particles” command. Parameters for 
analysis of IBA1-positive cells were set in pixel units excluding any object under 
400±100 or above 4500±1000 square pixel units. Objects positioned at the edge 
of the image field were excluded. For analysis of cell process count and length, 
primary processes extending directly from the cell body and no shorter than 5 
microns in length were counted and measured. 5-6 IBA1-positive cells per image 
field were analyzed for average process count and length measurements. For all 
morphological analyses, final measurements were reported in microns (resolution 
of 6.2 pixels per micron). 
 
Isolation of nucleus accumbal microglia and astrocytes by magnetic 
activated cell sorting (MACS) 
Nucleus accumbal tissues were diced with a sterile scalpel into small pieces in a 
sterile petri dish containing 2 ml of cold Hank’s buffered saline solution (HBSS, 
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minus Ca2+, Mg2+; Life Technologies Corporation, Grand Island, NY, USA). This 
suspension was transferred into a 15 ml centrifuge tube, and then, spun at 300Xg 
for 2 minutes at 4 oC. Supernatant was discarded, and tissue was processed into 
single-cell suspension by enzyme dissociation using Miltenyl’s adult brain 
dissociation kit (Miltenyl Biotec Inc., Auburn, CA, USA) according to the 
manufacturer’s instructions. Following complete dissociation, cell suspension was 
applied to pre-wet MACS Smart Strainer (70 μm; Miltenyl Biotec Inc., Auburn, CA, 
USA), and the flow through was processed for microglia labeling with CD11b+ 
microbeads (Miltenyl Biotec Inc., Auburn, CA, USA). Cells were washed with 2 ml 
0.5% BSA in PBS buffer and centrifuged at 300Xg for 10 minutes at 4 oC for 
removal of any unbounded beads from the pellet. Cell pellet was re-suspended in 
500μl 0.5% BSA in PBS buffer, and then applied onto a prepped MACS MS column 
attached to an OctoMACS magnetic separator (Miltenyl Biotec Inc., Auburn, CA, 
USA). Flow through containing unlabeled cells was collected first, and CD11b+ 
microglia were then collected by flushing out the magnetically labeled cells in the 
column into a microcentrifuge tube following the removal of the column from the 
magnetic separator. The flow through was immediately processed for astrocyte 
labeling using anti-ACSA-2 microbead kit (Miltenyl Biotec Inc., Auburn, CA, USA) 
according to the manufacturer’s instructions. In a similar way to the magnetic 
separation step in CD11b+ microglia isolation, ACSA-2+ astrocytes were also 





Behavioral and molecular data analyses 
Results are presented as mean ± SEM. For behavioral data, statistical differences 
between groups were determined using two-way ANOVA followed by multiple two-
stage linear step-up procedure of Benjamini, Krieger and Yekutieli multiple 
comparisons test. For molecular data, statistical differences between groups were 
determined using either one-way or two-way ANOVA followed by Bonferroni’s or 
Tukey’s HSD multiple comparison test. All statistical analyses were done in 
GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA, USA).  
 
2.4    RESULTS 
Chronic nicotine and withdrawal alter microglial morphology in the nucleus 
accumbens. 
Morphological changes and release of pro-inflammatory cytokines are canonical 
features of activated microglia (Bollinger et al 2016, Ding et al 2017, Qin et al 
2004). To evaluate both features during chronic nicotine and withdrawal, mice 
were administered saline or nicotine (18 mg/kg/day) via osmotic minipump 
implantation, and at 2 weeks, a 48-h withdrawal was initiated by removal of 
implanted pumps in mice earmarked for nicotine withdrawal and their saline 
controls (Figure 2.1a). Our evaluation of striatal microglia morphology revealed 
region-specific alterations following chronic nicotine and withdrawal. In the nucleus 
accumbens of chronic nicotine and withdrawal mice, there were more microglia 
with larger cell area (F = 18.24, p < 0.0001, ANOVA; Saline versus Chronic nicotine 
mice: p < 0.0001, Saline versus Nicotine withdrawal mice: p = 0.0169, Post-hoc 
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analyses), larger cell perimeter (F = 6.390, p = 0.0018, ANOVA; Saline versus 
Chronic nicotine mice: p = 0.0026, Sal versus Nicotine withdrawal mice: p = 
0.0254, Post-hoc analyses), but not process length (F = 1.331, p = 0.2654, 
ANOVA) compared to their saline counterparts; however, in the caudate putamen, 
we observed differences only between the microglial process length of chronic 
nicotine and withdrawal mice (Cell area: F = 2.917, p = 0.0547, ANOVA; Cell 
perimeter: F = 1.121, p = 0.3264, ANOVA; Process length: F = 3.697, p = 0.0256, 
ANOVA; Saline versus Chronic nicotine mice: p = 0.1848, Sal versus Nicotine 
withdrawal mice: p = 0.6310, Chronic nicotine versus Nicotine withdrawal mice: p 
= 0.0292, Post-hoc analyses) (Figure 2.1b – c, i - iii). While these data show that 
chronic nicotine and withdrawal induce microglia activation in the nucleus 
accumbens, our microglial process length data suggest that the observed 
activation phenotype may be early in the microglia activation spectrum. Next, we 
evaluated mRNA expression levels of TNFα and IL1β – pro-inflammatory cytokines 
associated with microglia activation, and our qPCR results revealed a differential 
mRNA profile of these cytokines in chronic nicotine and withdrawal mice. In the 
nucleus accumbens, TNFα (F = 8.429, p = 0.0009, ANOVA; Saline versus Nicotine 
withdrawal mice: p = 0.0032, Chronic nicotine versus Nicotine withdrawal mice: p 
= 0.0015, Post-hoc analyses) and IL1β (F = 6.698, p = 0.0027, ANOVA; Saline 
versus Nicotine withdrawal mice: p = 0.0179, Chronic nicotine versus Nicotine 
withdrawal mice: p = 0.0023, Post-hoc analyses) mRNA levels were elevated in 
the nicotine withdrawal mice compared to chronic saline and nicotine counterparts, 
suggesting a muted pro-inflammatory signal during chronic nicotine treatment. In 
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contrast, in the caudate-putamen, there was a significant decrease in IL1β mRNA 
expression (F = 3.903, p = 0.0269, ANOVA; Saline versus Nicotine withdrawal 
mice: p = 0.0361, Chronic nicotine versus Nicotine withdrawal mice: p = 0.0415, 
Post-hoc analyses), but no significant change in TNFα mRNA expression (F = 
3.140, p = 0.0538, ANOVA) between treatment groups (Figure 2.1d and e). Taken 
together, these results demonstrate that chronic nicotine and withdrawal induce 
microglial activation with distinct molecular features in the nucleus accumbens.   
 
Nicotine withdrawal induces reactive oxygen species in the nucleus 
accumbens.  
Given that excessive production of ROS is often associated with microglial 
activation (Ding et al 2017), we directly examined ROS generation in the nucleus 
accumbens and caudate putamen of saline, chronic nicotine, and nicotine 
withdrawal mice using a protein carbonylation assay. Carbonylated proteins are 
well-established markers for oxidative stress because they are representative 
products of protein oxidation, which occurs either by direct or indirect reaction of a 
protein with ROS or secondary by-products of oxidative stress (Suzuki et al 2010b, 
Zhang et al 2013) (Figure 2.2a; Protein and arrow icons were downloaded from 
Reactome (Sidiropoulos et al 2017)). In agreement to our previous observations 
of TNFα and IL1β mRNA levels, we found that nicotine withdrawal animals had 
increased levels of carbonylated proteins (F = 9.125, p = 0.0004, ANOVA; Saline 
versus Nicotine withdrawal mice: p = 0.0012, Chronic nicotine versus Nicotine 
withdrawal mice: p = 0.0019, Post-hoc analyses) in the nucleus accumbens 
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compared to the chronic saline and nicotine equivalents, while there were no 
changes (F = 0.3290, p = 0.7247, ANOVA) between treatment groups in the 
caudate putamen (Figure 2.2b and c). These data further reinforce that the 
observed dissimilar pro-inflammatory signaling during chronic nicotine and 
withdrawal is specific to the nucleus accumbens. 
 
N-acetylcysteine prevents microglial signaling, but not activation, in the 
nucleus accumbens during nicotine withdrawal. 
While we have shown that nicotine withdrawal induces ROS generation in the 
nucleus accumbens, it is unclear whether altered microglial morphology and 
signaling during nicotine withdrawal can be attenuated by ROS scavenging. To 
examine this, we utilized N-acetylcysteine (NAC), a well-described antioxidant 
(Aruoma et al 1989, Dekhuijzen 2004, Sun 2010). In this experiment, animals were 
administered saline or nicotine (18 mg/kg/day) via osmotic minipump implantation, 
and at 2 weeks, a 48 h withdrawal was initiated by removal of implanted pumps in 
animals earmarked for nicotine withdrawal and their saline controls. A day prior to 
withdrawal and each morning for the next 3 days, all animals received either 
vehicle or NAC (150 mg/kg per day) injection intraperitoneally (Figure 2.3a). First, 
we evaluated the impact of NAC on nicotine withdrawal-induced pro-inflammatory 
cytokines in the nucleus accumbens. Our TNFα qPCR results show that there was 
a main effect of nicotine withdrawal (F(2, 88) = 13.51, p = 0.0001, ANOVA), but no 
main effect of NAC injection (F(1, 88) = 0.02802, p = 0.8674, ANOVA) or an 
interaction effect (F(2, 88) = 2.503, p = 0.0876, ANOVA). Post-hoc analyses 
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demonstrated vehicle-treated nicotine withdrawal mice showed increased TNFα 
mRNA expression in the nucleus accumbens compared to their nicotine 
counterparts and saline controls (p = 0.0040; p = 0.0031, respectively). In addition, 
TNFα message also increased in the nucleus accumbens of the NAC-treated 
nicotine withdrawal mice compared to vehicle-treated nicotine mice and saline 
controls (p = 0.0476; p = 0.0408, respectively) (Figure 2.3b). Our IL1β mRNA 
expression data show there was a main effect of nicotine withdrawal (F(2, 86) = 
6.026, p = 0.0036, ANOVA), but no main effect of NAC injection (F(1, 86) = 3.269, 
p = 0.0741, ANOVA) or an interaction effect (F(2, 86) = 1.041, p = 0.3575, 
ANOVA). Post-hoc analyses demonstrated that while vehicle-treated nicotine 
withdrawal mice showed increased IL1β mRNA expression in the nucleus 
accumbens compared to their nicotine counterparts and saline controls (p = 
0.0029; p = 0.0221, respectively), IL1β message in the nucleus accumbens of the 
NAC-treated nicotine withdrawal mice was not significantly different from their 
vehicle-treated nicotine mice and saline controls (Figure 2.3c). Similarly, analysis 
of carbonylated protein levels in the nucleus accumbens indicated a main effect of 
nicotine withdrawal (F(2, 84) = 7.068, p = 0.0015, ANOVA), but no main effect of 
NAC treatment (F(1, 84) = 1.148, p = 0.2870, ANOVA) or an interaction effect (F(2, 
84) = 2.929, p = 0.0589, ANOVA).  Post-hoc analyses showed that vehicle-treated 
nicotine withdrawal mice had increased amounts of carbonylated proteins 
compared to their nicotine equivalents and saline controls (p = 0.0049; p = 0.0028; 
respectively).  In contrast, levels of this ROS marker were not significantly different 
between NAC-treated nicotine withdrawal mice and their respective vehicle-
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treated nicotine mice and saline controls (p = 0.7903; p = 0.7941) (Figure 2.3d and 
e). Next, we evaluated the impact of NAC on WD-induced microglial activation, 
and we observed that the nucleus accumbens level of microgliosis was unchanged 
with respect to the cell area (t(274) = 0.09383, p = 0.9253, unpaired t-test), cell 
perimeter (t(275) = 0.8845, p = 0.3772, unpaired t-test) and process length (t(189) 
= 0.5959, p = 0.5520, unpaired t-test) between nicotine withdrawal mice and their 
NAC-treated counterparts (Figure 2.4a and b, i - iii). Overall, these data show that 
while NAC treatment has no impact on morphological hallmarks of microglial 
activation, it was able to attenuate nicotine withdrawal-induced ROS in the nucleus 
accumbens.  
 
N-acetylcysteine attenuates nicotine withdrawal-induced anxiogenic 
behavior in mice. 
Given recent studies supporting the role of the nucleus accumbens in anxiety-
related disorders (Kim et al 2008, Levita et al 2012), we evaluated NAC effect and 
withdrawal from chronic nicotine in two well-validated behavioral models of anxiety, 
the marble-burying (MB) test and the open field (OF) test. These behavioral tests 
were conducted 30 minutes post-injection at 24-h (OF test) and 48-h (MB test) 
withdrawal time points (refer to Figure 2.3a). In the MB test, there was a significant 
interaction between the main effects (Treatment effect: F(2, 90) = 1.350, p = 
0.2644, ANOVA; Injection effect: F(1,90) = 1.002, p = 0.3195, ANOVA; Interaction: 
F(2, 90) = 5.642, p = 0.0049, ANOVA). Post-hoc analyses showed that vehicle-
treated nicotine withdrawal animals buried more marbles than their saline controls 
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(q = 0.0330), as well as their nicotine and NAC-treated equivalents (q = 0.0148; q 
= 0.0148, respectively) (Figure 2.5a), indicative of an anxiogenic effect. In the OF, 
there was a significant interaction between the main effects (Treatment effect: F(2, 
90) = 2.524, p = 0.0858, ANOVA; Injection effect: F(1,90) = 0.1591, p = 0.6910, 
ANOVA; Interaction: F(2, 90) = 5.079, p = 0.0081, ANOVA). From our post-hoc 
analyses, we discovered that vehicle-treated nicotine withdrawal animals spent 
less time in the center of the arena compared to their nicotine counterparts and 
saline controls (q = 0.0042; q = 0.0042), indicating an anxiogenic response. This 
is in contrast to NAC-treated nicotine withdrawal animals, which were not 
significantly different from vehicle-treated nicotine mice and their saline controls 
(Figure 2.5b and c). Further, these effects were not due to alterations in locomotor 
activity, as there were no differences in distance traveled between any of the 
treatment groups (Treatment effect: F(2, 91) = 2.713, p = 0.0717, ANOVA; Injection 
effect: F(1, 91) = 0.08425, p = 0.7723, ANOVA; Interaction: F(2, 91) = 2.379, p = 
0.0984, ANOVA) (Figure 2.5d). Altogether, these results suggest a role for nucleus 
accumbal oxidative stress in the development of nicotine withdrawal-related 
anxiety. 
 
Microglia-related NADPH oxidase 2 is increased in the nucleus accumbens 
during nicotine withdrawal. 
Among the many molecular mechanisms of intracellular ROS generation (Orient 
et al 2007), the NADPH oxidase (Nox) system is a major source of intracellular 
ROS production in the brain (Guilarte et al 2016, Rastogi et al 2016). Therefore, to 
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evaluate whether this system is the molecular source of WD-induced ROS, we 
examined the nucleus accumbens for changes in the primary Nox isoforms 
expressed in the brain. Quantitative PCR analysis of Nox1 (Treatment effect: F(2, 
91) = 0.7784, p = 0.4622, ANOVA; Injection effect: F(1, 91) = 0.7397, p = 0.3920, 
ANOVA; Interaction: F(2, 91) = 0.4887, p = 0.6150, ANOVA) and Nox4 (Treatment 
effect: F(2, 92) = 0.1001, p = 0.9049, ANOVA; Injection effect: F(1, 92) = 0.01189, 
p = 0.7310, ANOVA; Interaction: F(2, 92) = 1.521, p = 0.2240, ANOVA) in the 
nucleus accumbens showed no significant differences between treatment groups. 
However, qPCR analyses of Nox2, which is primarily expressed in the microglia 
(Zhang et al 2016), showed significant treatment and interactive effects (Treatment 
effect: F(2, 87) = 9.726, p = 0.0002, ANOVA; Injection effect: F(1, 87) = 3.563, p = 
0.0624, ANOVA; Interaction: F(2, 87) = 3.731, p = 0.0279, ANOVA). Post-hoc 
analyses showed that Nox2 mRNA expression was significantly increased in the 
nucleus accumbens of vehicle-treated nicotine withdrawal mice compared to their 
saline controls (p = 0.0006), as well as their nicotine and NAC-treated equivalents 
(p = 0.0002; p = 0.0221, respectively) (Figure 2.6a, i - iii). Of note, no significant 
differences in Nox2 mRNA expression were observed in the caudate putamen 
(Treatment effect: F(2, 86) = 0.5177, p = 0.5977, ANOVA; Injection effect: F(1, 86) 
= 0.1992, p = 0.6565, ANOVA; Interaction: F(2, 86) = 1.142, p = 0.3238, ANOVA) 
(Figure 2.6b). Further analyses investigating Nox2 protein show there was a main 
effect of nicotine withdrawal (F(2, 79) = 5.405, p = 0.0063, ANOVA), but no main 
effect of NAC injection (F(1, 79) = 0.01378, p = 0.9068, ANOVA) or an interaction 
effect (F(2, 79) = 0.5078, p = 0.6038, ANOVA). Post-hoc analyses demonstrated 
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that while vehicle-treated nicotine withdrawal mice showed increased Nox2 protein 
expression in the nucleus accumbens compared to their saline controls (p = 
0.0138), Nox2 levels in the nucleus accumbens of NAC-treated nicotine withdrawal 
mice was not significantly different from the levels in the vehicle-treated nicotine 
mice and their saline controls (p = 0.9000; p = 0.1070, respectively) (Figure 2.6c). 
Altogether, these data support that increased nucleus accumbal Nox2 during 
nicotine withdrawal contributes significantly to ROS production underlying nicotine 
withdrawal-related anxiety. Given that previous studies investigating Nox 
expression in brain cell-types induced Nox with lipopolysaccharide or examined 
Nox in pathological states (Nayernia et al 2014), we evaluated the enrichment of 
Nox isoforms at baseline in both neuronal and glial cell-types. We utilized magnetic 
activated cell sorting (MACS) for isolation and purification of cell-types in nucleus 
accumbens tissue. The purified cells were validated and investigated for Nox 
expression using qPCR. Our validation of microglia showed that CD11b+ (F = 
344.1, p < 0.0001, ANOVA; Total Homogenate versus CD11b+ microglia: p < 
0.0001, Post-hoc analysis), Tmem119 (F = 120.2, p < 0.0001, ANOVA; Total 
Homogenate versus CD11b+ microglia: p < 0.0001, Post-hoc analysis), and 
P2ry12 (F = 75.70, p < 0.0001, ANOVA; Total Homogenate versus CD11b+ 
microglia: p < 0.0001, Post-hoc analysis) were highly enriched in CD11b+ microglia 
compared to total homogenate; however, there was no significant difference in 
expression of these microglia markers in total homogenate compared to ACSA II 
astrocytes, liver, neurons and oligodendrocytes (Figure 2.7a, i - iii). While Nox1 (F 
= 6.452, p = 0.0032, ANOVA; Total Homogenate versus Liver: p = 0.0034, Post-
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hoc analysis) and Nox4 (F = 10.31, p = 0.0006, ANOVA; Total Homogenate versus 
Liver: p = 0.0021, Post-hoc analysis) mRNA analyses showed significant 
enrichment in the liver compared to total homogenate, there were no significant 
differences between total homogenate and the evaluated brain cell-types (Figure 
2.7b, i and ii). In contrast, Nox2 mRNA is significantly enriched in both microglia (F 
= 9.995, p = 0.0002, ANOVA; Total Homogenate versus CD11b+ microglia: p = 
0.0005, Post-hoc analysis) and liver (F = 9.995, p = 0.0002, ANOVA; Total 
Homogenate versus Liver: p < 0.0305, Post-hoc analysis) compared to total 
homogenate, which is not significantly different from ACSA II astrocytes, neurons 
and oligodendrocytes (Figure 2.7b, iii). Altogether, these data suggest that 
microglia-related Nox2 significantly contributes to excessive nucleus accumbal 
ROS generation and associated anxiety-like behavior during nicotine withdrawal. 
 
Microglia depletion blocks increases in nicotine withdrawal-induced NADPH 
oxidase 2 and reactive oxygen species in the nucleus accumbens and 
attenuates nicotine withdrawal-related anxiety 
Microglia are actively involved in the brain’s functional organization (Perry et al 
2010, Salter & Stevens 2017), which can be altered by chronic drug use or 
withdrawal. Our studies have demonstrated that withdrawal from chronic nicotine 
use, but not chronic nicotine treatment, elicits microglial morphological changes 
accompanied with pro-inflammatory signals in the nucleus accumbens (Figure 2.1, 
b - e). Therefore, to understand the contribution of this microglial phenotype in the 
development of withdrawal-related anxiety, we pharmacologically knocked down 
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microglia in saline and nicotine withdrawal animals using PLX5622, which is a 
colony stimulating factor-1 receptor (CSF1R) inhibitor. Both saline and nicotine 
withdrawal animals were fed either control- or PLX5622-chow 7 days after 
receiving chronic saline or nicotine treatment via osmotic minipump implantation. 
Withdrawal from chronic saline or nicotine lasted 48 h. OF and MB test were 
conducted at 24-h and 48-h withdrawal time points respectively (Figure 2.8a). Our 
evaluation of microglia density in the nucleus accumbens showed a significant 
main effect of PLX5622 chow and an interaction effect (Treatment effect: F(1, 17) 
= 0.02218, p = 0.8834, ANOVA; Chow effect: F(1, 17) = 54.39, p < 0.0001, ANOVA; 
Interaction: F(1, 17) = 4.705, p = 0.0445, ANOVA). Post-hoc analyses showed 
significant decrease in Iba1+ cells / mm2 (Saline Control-chow versus Saline 
PLX5622-chow: p <0.0001; Nicotine withdrawal Control-chow versus Nicotine 
withdrawal PLX5622-chow: p = 0.0107) in the nucleus accumbens of the 
PLX5622-treated animals compared to their controls (Figure 2.8b, i and ii). Further, 
we evaluated microglia depletion in the nucleus accumbens using well-validated 
microglia markers. Both Tmem119 (Treatment effect: F(1, 34) = 0.06459, p = 
0.8009, ANOVA; Chow effect: F(1, 34) = 917.4, p < 0.0001, ANOVA; Interaction: 
F(1, 34) = 1.632, p = 0.2101, ANOVA) and P2ry12 (Treatment effect: F(1, 34) = 
0.03939, p = 0.8439, ANOVA; Chow effect: F(1, 34) = 461.5, p < 0.0001, ANOVA; 
Interaction: F(1, 34) = 0.2781, p = 0.6014, ANOVA) mRNA only showed  significant 
main effect of PLX5622 chow. Similar to observations with Iba1+ cells / mm2 
quantitation, our post-hoc analyses revealed significant reduction in Tmem119 
(Saline Control-chow versus Saline PLX5622-chow: p <0.0001; Nicotine 
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withdrawal Control-chow versus Nicotine withdrawal PLX5622-chow: p <0.0001) 
and P2ry12 (Saline Control-chow versus Saline PLX5622-chow: p <0.0001; 
Nicotine withdrawal Control-chow versus Nicotine withdrawal PLX5622-chow: p 
<0.0001) mRNA expression in PLX5622-treated animals compared to their 
controls (Figure 2.8c, i - ii). However, given that CSF1R are also expressed on 
macrophages, we examined whether there could be involvement of infiltrating 
macrophages in our study by comparing the expression profile of Tmem119 and 
P2ry12 to C-C-chemokine receptor 2 (Ccr2), which has been previously described 
by many studies as a critical element for trafficking and assembly of myeloid cells 
in the brain (Mizutani et al 2012, Morganti et al 2015, Prinz & Priller 2010, 
Saederup et al 2010). In the nucleus accumbens, our data showed an extremely 
low Ccr2 expression compared to Tmem119 and P2ry12 in all treatment groups. 
In addition, CSF1R inhibition did not reduce Ccr2+ macrophages compared to 
controls in the nucleus accumbens (Figure 2.8d). Next, we examined the impact 
of microglia depletion on Nox2 expression in the nucleus accumbens during 
nicotine withdrawal. Similar to our validation of microglia depletion with microglia 
markers, our Nox2 qPCR analyses showed a significant chow effect (Treatment 
effect: F(1, 32) = 4.077, p = 0.0519, ANOVA; Chow effect: F(1, 32) = 20.10, p < 
0.0001, ANOVA; Interaction: F(1, 32) = 3.29, p = 0.0791, ANOVA). Post-hoc 
analyses showed that Nox2 mRNA expression was significantly increased in the 
nucleus accumbens of control-chow nicotine withdrawal mice compared to their 
saline controls (p = 0.0417) and PLX5622-chow equivalents (p = 0.0006) (Figure 
2.9a). Furthermore, we evaluated the effect of microglia knockdown on nicotine 
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withdrawal-induced ROS in the nucleus accumbens. We found a significant 
interactive effect between treatment and chow (Treatment effect: F(1, 31) = 1.661, 
p = 0.2070, ANOVA; Chow effect: F(1, 31) = 2.371, p = 0.1337, ANOVA; 
Interaction: F(1, 31) = 4.447, p = 0.0431, ANOVA). Similar to Nox2 mRNA 
evaluation in these animals, our post-hoc analyses showed an increase in 
carbonylated protein in the nucleus accumbens of control-chow nicotine 
withdrawal mice compared to their saline controls (p = 0.0412) and PLX5622-chow 
counterparts (p = 0.0270) (Figure 2.9b, i and ii). Finally, we assessed the 
behavioral impact of microglia depletion during nicotine withdrawal. For MB test, 
there was a significant main effect of nicotine withdrawal (Treatment effect: F(1, 
35) = 4.637, p = 0.0383, ANOVA; Chow effect: F(1, 35) = 1.733, p = 0.1966, 
ANOVA; Interaction: F(1, 35) = 1.937, p = 0.1728, ANOVA). While our post-hoc 
analyses showed an increase in the amount of marbles buried by the control-chow 
nicotine withdrawal mice compared to their saline controls (q = 0.0187), there was 
no observable difference between the PLX5622-chow nicotine withdrawal mice 
and their saline equivalents (q = 0.5630) (Figure 2.9c). Our OF analyses 
demonstrated a significant main effects of nicotine withdrawal and PLX5622 chow 
(Treatment effect: F(1, 35) = 19.18, p = 0.0001, ANOVA; Chow effect: F(1, 35) = 
5.736, p = 0.0221, ANOVA; Interaction: F(1, 35) = 0.08795, p = 0.7685, ANOVA). 
From our post-hoc analyses, we found that control-chow nicotine withdrawal mice 
spent less time in the center of the arena compared to their PLX5622-chow 
counterparts (q = 0.0031) and saline controls (q = 0.0487) (Figure 2.9, d and e). 
There were no observed differences in distance moved between animals from all 
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treatment groups (Figure 2.9f). Overall, these data show that microglia depletion 
reduced aberrant nucleus accumbal oxidative signaling and associated anxiogenic 
behaviors.  
 
2.5    DISCUSSION 
Altered microglial signaling and associated neuroinflammation are well known key 
molecular events in the onset and progression of several neurodegenerative 
diseases (Chen et al 2016, Cunningham 2013, Perry et al 2010); however, their 
role in nicotine dependence has not been previously investigated. We show that 
chronic nicotine and withdrawal trigger microglial morphological changes with 
dissimilar activation phenotypes in the nucleus accumbens, and that the microglial 
activation phenotype during nicotine withdrawal is of a pro-inflammatory pattern. 
Further, we report elevated ROS levels in the nucleus accumbens only during 
nicotine withdrawal and show evidence that Nox2, which is highly enriched in 
microglia, is the major ROS-producing machinery. However, in contrast to our 
findings in the nucleus accumbens, we show that both chronic nicotine and 
withdrawal trigger none of these effects in the caudate putamen. Using a well-
described antioxidant, we reveal a role for nucleus accumbal oxidative stress in 
the development of nicotine withdrawal-related anxiety. More directly, after 
depleting microglia to evaluate their role in connection to oxidative stress signals 
in the nucleus accumbens during nicotine withdrawal, we show reduced Nox2 
mRNA and ROS in the nucleus accumbens, as well as associated nicotine 
withdrawal-related anxiety. Together, our study suggests that unlike other drugs of 
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abuse such as cocaine, which directly elicits a microglial activation phenotype 
associated with TNFα increase in the nucleus accumbens (Lewitus et al 2016a), 
nicotine exposure results in unchanged nucleus accumbal levels of TNFα 
regardless of microglial activation; however, acute withdrawal from nicotine 
provokes microglial activation as well as increased TNFα levels in the nucleus 
accumbens. Lastly, our data provide the first evidence that altered microglia 
morphology and function significantly contribute to the development of anxiety-like 
behavior during nicotine withdrawal.  
  
Microglial Activation Phenotypes during Chronic Nicotine and Withdrawal in 
the Striatum. 
Microglia are central players in an increasing number of brain disorders (Salter & 
Stevens 2017), and understanding their responsivity and role in nicotine 
dependence becomes increasingly urgent. In our model, both chronic nicotine and 
withdrawal induce remodeling of the highly adaptable resting microglia in the 
nucleus accumbens, but not in the caudate putamen, suggesting that microglial 
responsivity to drug cues may be shaped by the specialized role of their local CNS 
environment. For example, a recent study examining microglia transcriptome 
across the basal ganglia reported regional heterogeneity of resident microglia, and 
indicated local cues as a critical mediator of microglia phenotype and their diversity 
(De Biase et al 2017). In addition, this study also showed that genes associated 
with oxidative signaling and ROS homeostasis are among the top 10 abundant 
genes in nucleus accumbal microglia, but not microglia from other parts of the 
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basal ganglia (De Biase et al 2017). This is consistent with our findings that show 
disruption in ROS homeostasis in the nucleus accumbens, but not the caudate 
putamen, during nicotine withdrawal. Another important finding is the dissimilar 
expression of pro-inflammatory cytokines (TNFα, IL1β) and ROS in the nucleus 
accumbens during chronic nicotine and withdrawal. This suggests distinct pro-
inflammatory profile, which may be partly driven by the diverse phenotype of 
activated microglia in both treatment conditions. In line with clinical studies that 
have shown nicotine’s neuroprotective property in certain neurodegenerative 
diseases (Newhouse et al 2012, Villafane et al 2007), our findings show an 
absence of TNFα and IL1β mRNA induction during chronic nicotine treatment, 
suggesting a muted pro-inflammatory response in the striatum. However, the 
molecular attributes of activated microglia during withdrawal from chronic nicotine 
are characteristic of the pro-inflammatory phenotype. Of note, the few studies 
available on the role of microglia in drug dependence reported that microglial 
activation and related pro-inflammatory effects were directly elicited by the drugs 
of abuse examined, namely cocaine (Lewitus et al 2016a) and morphine 
(Hutchinson et al 2009, Schwarz & Bilbo 2013). Similar to our findings, microglial 
activation and elevated levels of pro-inflammatory signals in those studies were 
limited to the nucleus accumbens, but our findings contrast with those earlier 
studies in that activation of nucleus accumbal pro-inflammatory signals occur only 
during withdrawal from nicotine and not due to exposure to nicotine itself. Microglia 
are primarily involved in synaptic function and plasticity; however, their alteration 
within the nucleus accumbens, which is a critical brain circuit for addictive 
 
 51 
processes, can enhance the development of aberrant synaptic connections and 
plasticity underlying nucleus accumbal adaptive changes in drug dependency 
(Grueter, Rothwell, & Malenka, 2012). Together, it is becoming clear that the 
synaptic cues specific to the nucleus accumbens during chronic nicotine and 
withdrawal influence its resident microglia signature. 
 
Microglial NADPH Oxidase 2 Regulation in the Nucleus Accumbens during 
Nicotine Withdrawal 
NADPH oxidase (Nox) systems are primarily implicated in disease-related aberrant 
ROS production (Panday et al 2015). Among the primary Nox isoforms in the brain 
– Nox1, Nox2, and Nox4 (Ma et al 2017), our findings implicate Nox2 as the 
primary source of excessive ROS in the nucleus accumbens during nicotine 
withdrawal. Many studies have reported that Nox2 is highly enriched in microglia 
compared to other brain cell-types (Guilarte et al 2016, Nayernia et al 2014, Zhang 
et al 2014, Zhang et al 2016) and a previous study also provided additional 
evidence showing that lipopolysaccharide (LPS) stimulation of BV2 microglial cell 
lines resulted in Nox2-dependent ROS production (Huo et al 2011). In our study, 
we find that among the brain cell-types, Nox2 is primarily expressed only in 
microglia at baseline. Overall, this study suggests that microglia-related Nox2 
contributes significantly to aberrant ROS levels in the nucleus accumbens during 




N-acetylcysteine Effects and Anxiety-like Behavior during Nicotine 
Withdrawal. 
Our behavioral findings provide a link between oxidative stress and anxiety-like 
behavior during nicotine withdrawal. NAC treatment prior to nicotine withdrawal 
precluded Nox2 induction and reduced ROS levels in the nucleus accumbens, a 
brain region well described for its critical role in anxiety (Kim et al 2008, Levita et 
al 2012, van der Kooij et al 2018). Together, NAC treatment results in attenuation 
of anxiety-like behavior during nicotine withdrawal. While this interpretation relies 
on NAC’s well-documented antioxidant effects, other mechanisms describing 
NAC’s effects in nicotine dependence phenotypes have been previously described 
(Gipson et al 2013, Knackstedt et al 2009). For example, Knackstedt et al (2009) 
demonstrated that NAC treatment in smokers reduced the number of cigarettes 
smoked by study participants.  The authors attributed this effect in smokers to 
NAC’s modulation of the astrocytic cystine-glutamate exchanger (xCT), which was 
initially shown to be compromised in their preclinical studies investigating nicotine 
seeking in rats (Knackstedt et al 2009). Of note, in their rodent experiment, while 
xCT was downregulated in rats that self-administered nicotine, the xCT was 
unchanged in animals that received nicotine via osmotic minipump, suggesting a 
motivational rather than a pharmacological basis for changes in xCT during 
nicotine exposure. Given that our findings are from mice treated with chronic 
nicotine via osmotic minipump, our results are unlikely to be due to NAC’s 
modulatory effects on the xCT, but more likely due to its extensively described 
antioxidant activity (Aruoma et al 1989, Dekhuijzen 2004, Sun 2010). Furthermore, 
 
 53 
while our studies demonstrated that NAC treatment effectively attenuated 
microglia-related ROS and the associated anxiety-like phenotypes, we also show 
that NAC is ineffective in altering the microglial activation phenotype during 
nicotine withdrawal. Given this limitation, combining NAC with therapeutics that 
can inhibit microglial reprogramming to an activation phenotype, such as 
minocycline (Suzuki et al 2010a, Zhu et al 2014), or those that can reverse the 
activation phenotype may offer more effective treatment for smoking cessation. 
 
Microglia Depletion and Anxiety-like Behavior during Nicotine Withdrawal 
Several studies have implicated microglial function in anxiety-related disorders (Li 
et al 2014, Stein et al 2017, Wang et al 2018); however, the role of microglia in 
nicotine withdrawal-related anxiety is unknown. Our study shows that depletion of 
microglia during nicotine withdrawal reduced Nox2 and ROS levels in the nucleus 
accumbens, and consequently attenuated nicotine withdrawal-related anxiety. 
These findings provide a strong link between microglia function and nicotine 
withdrawal-related anxiety, and further reinforce the contribution of microglial Nox2 
and associated aberrant ROS production in the nucleus accumbens to the 
development of anxiety-like behavioral phenotype during nicotine withdrawal.  
 
Perspectives on Future Smoking Cessation Pharmacotherapies 
Currently, there are three FDA-approved pharmacotherapies for smoking 
cessation:  varenicline (a nicotinic selective partial agonist), bupropion (a 
norepinephrine-dopamine reuptake inhibitor), and nicotine replacement therapy 
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(NRT, as patch, gum, etc.).  While each of these therapeutics have quantifiable 
success as smoking cessation aids, the best in class medication, varenicline, 
results in only 40% abstinence success at 12 weeks and less than 20% at one 
year post-quit (Gonzales et al 2006).  This underscores the urgent need for new 
drug targets in the development of new smoking cessation aids.  We outline a 
series of novel findings implicating neuroinflammatory responses during nicotine 
withdrawal, arising not from the combustible contents of cigarettes, but from 
nicotine withdrawal itself.  This suggests that withdrawal from two of the current 
smoking cessation aids, varenicline and NRT, may also alter neuroinflammatory 
responses in the mesolimbic circuitry.  Further, with e-cigarette use on the rise 
particularly in adolescents and young adults, our findings lend mechanistic insight 
into why vaping during adolescence promotes progression to combustible 
cigarettes as adults (Leventhal et al 2015, Primack et al 2015). Long-term, further 
investigation into modulators of microglial function during nicotine withdrawal 









Figure 2.1: Chronic nicotine and withdrawal induce different microglial activation 
phenotypes in the nucleus accumbens. a. Experimental design. b. Representative 
images of IBA1-positive microglia in the caudate putamen and nucleus accumbens of 
saline (Sal), nicotine (Nic), and nicotine withdrawal (WD) mice. i) White dotted traces 
delineate the caudate-putamen (dorsal) and nucleus accumbens (ventral); black dotted 
traces indicate area where image iv – ix were taken. Scale bar = 1mm. ii) resting microglia, 
and iii) activated microglia. Scale bar = 20μm. Caudate-putamen of iv) Sal mice, v) Nic 
mice, and vi) WD mice. Nucleus accumbens of vii) Sal mice, viii) Nic mice, and ix) WD 
mice. Scale bar = 100μm. c. Quantitation of IBA1-positive microglia morphology in the 
caudate putamen and nucleus accumbens. i) Cell area, ii) Cell Perimeter, iii) Process 
length. d. Bar charts showing TNFα mRNA expression in the nucleus accumbens and 
caudate-putamen of Sal, Nic, and WD mice. e. Bar charts showing IL1β mRNA expression 
in the nucleus accumbens and caudate-putamen of Sal, Nic, and WD mice. (Compared to 
Sal – *P<0.05, **P<0.01, ****P<0.0001; Compared to Nic – #P<0.05, ##P<0.01; c: n = 
minimum of 116 cells were quantified from 4-8 animals per treatment group; d, e: n=12-










Figure 2.2: Nicotine withdrawal induces reactive oxygen species in the nucleus 
accumbens. a. Schematic diagram showing mechanism of ROS detection by protein 
carbonylation assay (Protein and arrow icons were downloaded from Reactome 
(Sidiropoulos et al., 2017)). b. Representative immunoblot showing the presence of 
carbonylated protein (reactive oxygen species indicator) in Sal, Nic, and WD mice i) 
nucleus accumbens, ii) caudate putamen. c. Quantitation of 2b. (Compared to Sal – 


















Figure 2.3: N-Acetylcysteine attenuates nicotine withdrawal-induced reactive 
oxygen species in the nucleus accumbens. a. Experimental design. b. Bar chart 
showing nucleus accumbal mRNA expression of TNFα in vehicle- and NAC-treated Sal, 
Nic and WD mice c. Bar chart showing nucleus accumbal mRNA expression of IL1β in 
vehicle- and NAC-treated Sal, Nic and WD mice d. Representative immunoblot showing 
the expression of carbonylated proteins in the nucleus accumbens of vehicle- and NAC-
treated Sal, Nic and WD mice e. Quantitation of 3d. (Compared to Sal-Vehicle – *P<0.05, 











Figure 2.4: Nicotine withdrawal-induced microglia activation is unaltered by n-
acetylcysteine treatment. a. Representative images of IBA-1 positive microglia in the 
nucleus accumbens of i) vehicle-treated, and ii) NAC-treated nicotine withdrawal mice. 
Scale bar = 100μm. b. Quantitation of 4a. i) Cell area, ii) Cell Perimeter, iii) Process length. 












Figure 2.5: N-acetylcysteine treatment is anxiolytic during nicotine withdrawal. a. 
Marble-burying test: Bar graph showing the mean amount of marbles buried by vehicle- 
and NAC-treated Sal, Nic and WD mice. b. Representative open field traces of vehicle- 
and NAC-treated Sal, Nic and WD mice. c. Open field test: Bar chart showing percent time 
spent in the center of the open field arena by vehicle- and NAC-treated Sal, Nic and WD 
mice. d. Locomotor activity: Bar chart showing average distance moved in the open field 
arena by vehicle- and NAC-treated Sal, Nic and WD mice. (Compared to Sal-Vehicle – 
*q<0.05, **q<0.01; Compared to Nic-Vehicle – #q<0.05, ##q<0.01; Compared to WD-















Figure 2.6: Nicotine withdrawal increases Nox2 expression in the nucleus 
accumbens. a. Bar graph showing quantitative PCR analysis of NOX isoforms (primarily 
expressed in the brain) in the nucleus accumbens of vehicle- and NAC-treated Sal, Nic 
and WD mice. i) Nox1, ii) Nox2, and iii) Nox4. b. Bar graph showing quantitative PCR 
analysis of Nox2 mRNA expression in the caudate-putamen of vehicle- and NAC-treated 
Sal, Nic and WD mice. c. Western blot image and quantification of nucleus accumbal Nox2 
protein expression in vehicle- and NAC-treated Sal, Nic and WD mice. (Compared to Sal-
Vehicle – *P<0.05, ***P<0.001; Compared to Sal-NAC – &&P<0.01; Compared to Nic-

















Figure 2.7: Nox2 is expressed in microglia. a. Bar graph showing quantitative PCR 
analysis of microglia markers in the liver, brain cell-types and tissue (Total homogenate). 
i) CD11b, ii) Tmem119, and iii) P2ry12. b. Bar graph showing quantitative PCR analysis 
of Nox isoforms in the liver, brain cell-types and tissue. i) Nox1, ii) Nox4, and iii) Nox2. 
(Compared to Total homogenate – *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; a, b: 

















Figure 2.8: Inhibition of CSF1 receptor (CSF1R) depletes microglia in the nucleus 
accumbens. a. Experimental design. b. i) Representative images of IBA1-positive 
microglia in the nucleus accumbens of Control- and PLX5622-chow Sal, as well as their 
WD equivalents. ii) Quantitation of 8bi. c. Bar graph showing quantitative PCR analysis of 
microglia markers in the nucleus accumbens of Control- and PLX5622-chow Sal, as well 
as their WD equivalents. i) Tmem119, and ii) P2ry12. d. Heatmap showing normalized 
expression profile of Tmem119, P2ry12, and Ccr2 in the nucleus accumbens of Control- 
and PLX5622-chow Sal, as well as their WD equivalents. (Compared to Sal-Control – 
***P<0.001, ****P<0.0001; Compared to Sal-PLX5622 – ###P<0.001, ####P<0.0001; 
Compared to WD-Control – $P<0.05, $$$$P<0.0001; bii: n=5 per treatment group; c, d: 











Figure 2.9: Microglia depletion attenuates nicotine withdrawal-related anxiety. a. Bar 
graph showing quantitative PCR analysis of Nox2 in the nucleus accumbens of Control- 
and PLX5622-chow Sal, as well as their WD equivalents. b. i) Representative immunoblot 
showing the expression of carbonylated proteins in the nucleus accumbens of Control- 
and PLX5622-chow Sal, as well as their WD equivalents. ii) Quantitation of 9bi. c. Marble-
burying test: Bar graph showing the mean amount of marbles buried by Control- and 
PLX5622-chow Sal, as well as their WD equivalents. d. Representative open field traces 
of Control- and PLX5622-chow Sal, as well as their WD equivalents. e. Open field test: 
Bar chart showing percent time spent in the center of the open field arena by Control- and 
PLX5622-chow Sal, as well as their WD equivalents. f. Locomotor activity: Bar chart 
showing average distance moved in the open field arena by Control- and PLX5622-chow 
Sal, as well as their WD equivalents. (Compared to Sal-Control – *P<0.05, **P<0.01; 
Compared to Sal-PLX5622 – ##P<0.01, ###P<0.001; Compared to WD-Control – $P<0.05, 
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3.1    ABSTRACT 
Transcriptional programs are genomic regulatory code instructing the formation, 
maintenance, and functions of diverse brain cell types and distinct brain structures. 
Tissue- and cell type-specific evaluation of whole transcriptome can advance 
current understanding of the role of genes in CNS health and disorders such as 
nicotine dependence. Here, we performed whole transcriptome sequencing on 
nucleus accumbens microglia, astrocytes, and its whole tissue at different 
withdrawal timepoints (24 h and 48 h). We show temporally-dependent activation 
of distinct gene programs in the nucleus accumbens during chronic nicotine and 
withdrawal. Differential gene expression analysis suggests that chronic nicotine 
treatment activates subset of genes that are neuroprotective while withdrawal from 
nicotine provokes neuroinflammation and oxidative stress- related transcriptional 
programs in the nucleus accumbens. Our cell type-specific RNA seq data support 
our tissue-level observation. Gene programs associated with neuroinflammation 
were suppressed in microglia following nicotine treatment while nicotine 
withdrawal triggers microglial pro-inflammatory networks. Further, our 
transcriptome data suggest astrocytes assume a reactive phenotype during 
nicotine withdrawal. Finally, we find subset of genes that are enriched in nucleus 
accumbens tissue and either of the nucleus accumbens cell types examined during 
nicotine withdrawal. Taken together, our study provides the first insight into cell 
type-specific and tissue-level transcriptional remodeling in the nucleus accumbens 




3.2    INTRODUCTION 
Tobacco addiction impacts an estimated 1.2 billion people globally. While ability to 
successfully quit smoking remarkably reduces smoking-related deaths and 
diseases, about 80% of smokers attempting to quit fail (Benowitz 2010) due to the 
effect of nicotine, which is the addictive component of tobacco. Smoking cessation 
often leads to nicotine withdrawal symptoms, which usually manifest negative 
behavioral signs a few hours after discontinuation of nicotine use. These 
behavioral patterns are collections of affective and cognitive manifestations, which 
are both predictors of smoking relapse (Ashare et al 2014). Chronic exposure to 
drugs of abuse such as nicotine induces a number of neuroadaptations that result 
in drug dependence (Koob & Kreek 2007, Turner et al 2014). Such adaptations in 
neural circuits and associated functions are often required for maintenance of 
nicotine dependence. While the molecular mechanisms underlying the long-lasting 
nature of negative behaviors associated with nicotine dependence are not yet 
completely understood, it is recently becoming clearer that changes in specific 
gene programs in plastic neural circuits may underlie the development and 
persistence of these behaviors (Brunzell et al 2003, Nestler 2008, Turner et al 
2014). 
         The nucleus accumbens (NAc) is a heterogeneous structure that plays a 
central role in the mesolimbic reward pathway. Chronic exposure to many drugs 
of abuse including nicotine disrupt plasticity in the NAc circuitry, and these NAc-
related drug-induced neuroadaptations are known to underlie reward-related 
behaviors, which markedly contributes to relapse vulnerability in drug dependency. 
 
 68 
Besides several frequently-reported neuroadaptive changes in the NAc following 
chronic nicotine exposure, a few studies have demonstrated transcriptional 
changes relating to CREB (cAMP-response element-binding protein) and FosB (a 
Fos family protein) in this neurocircuitry (Brunzell et al 2009, Brunzell et al 2003, 
Nestler 2008). Alteration of transcription factors such as CREB and FosB is one of 
the common molecular mechanisms through which nicotine and other drugs of 
abuse regulate gene expression, which may underlie the persistence of addictive 
behaviors (Madsen et al 2012). Therefore, evaluation of NAc transcriptomic 
changes during chronic nicotine and withdrawal may reveal tissue-level bulk gene 
programs driving nicotine dependency. However, while quantification of tissue-
level transcriptome data may be a critical step towards advancing current 
understanding of nicotine dependence, this level of transcriptomic analyses may 
lack the actual resolution to better characterize the molecular phenotype 
associated with addictive disorders. In the complex multicellular NAc structure, 
there are neuronal and non-neuronal cell types such as astrocytes and microglia, 
which all together interact to maintain the integrity and adaptation of this neural 
circuitry (Allen & Barres 2009). Hence, evaluation of transcriptome-wide responses 
at cell-type specific resolution will provide a better understanding and a less 
complex insight into NAc-related molecular processes driving nicotine 
dependency.  
         In this study, we use RNA sequencing (RNA-seq) to capture temporal gene 
expression changes in nucleus accumbens tissue during chronic nicotine and 
withdrawal at different timepoints (24h and 48 h). Further, we explored 
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transcriptomic changes in the nucleus accumbens at cell type-specific resolution 
during chronic nicotine and 48 h withdrawal. We uncover multiple dysregulated 
genes and molecular pathways that are related to nicotine dependence. Our study 
provides the first direct evidence of transcriptome remodeling in the nucleus 
accumbens at cell type-specific and tissue-level resolution during chronic nicotine 
and withdrawal. 
 
3.3    MATERIALS AND METHODS 
Animals 
Male B6/129SF1 mice were purchased from Jackson Laboratories (Bar Harbor, 
ME, USA; 8 weeks of age; 20 – 31 g). Mice were housed in groups of four or five, 
and randomly assigned to treatment conditions. They were maintained on a 12-h 
light/dark cycle with food and water ad libitum in accordance to the University of 
South Carolina Animal Care and Use Committee. All behavioral testing sessions 
were conducted between the 0900 and 1300 hours. 
 
Osmotic drug delivery and treatment 
(-)-Nicotine tartrate (MP Biomedicals, Solon, OH, USA) was dissolved in sterile 
0.9% sodium chloride solution, and then infused subcutaneously via osmotic 
minipumps (Alzet model 2002; DURECT Corporation, Cupertino, CA, USA) at a 
dose of 18 mg/kg/day for 15 days. The control group was infused with saline for 
the same period of time. Chronic treatment with nicotine at this dose yields a 
plasma level of approximately 0.3μM in mice (reported as nicotine free base 
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molecular weight), a concentration comparable to that observed in human smokers 
consuming an average of 17 cigarettes a day (plasma levels between 0.06 - 
0.31μM) (Matta et al 2007). Prior to the start of surgery, mice were anesthetized 
with isoflurane/ oxygen mixture (1-3%), and minipumps were inserted using 
aseptic techniques. Surgical wounds were closed with 7mm stainless steel wound 
clips (Reflex, Cellpoint Scientific, Gaithersburg, MD, USA), after which mice were 
left to recover on the recovery pad before they were returned to their individual 
cages. After 14 days of chronic administration of either saline or nicotine via 
osmotic minipumps, mice earmarked for withdrawal from chronic nicotine and their 
assigned saline controls were subjected to spontaneous withdrawal by the removal 
of their osmotic minipumps using a similar aseptic surgical approach as above. 
Tissues were collected from mice after 24 h or 48 h withdrawal.   
 
Isolation of nucleus accumbal microglia and astrocytes by magnetic 
activated cell sorting (MACS) 
Nucleus accumbal tissues (10 pooled animals per N) from animals in the 48-h 
withdrawal experiment were diced with a sterile scalpel into small pieces in a sterile 
petri dish containing 2ml of cold Hank’s buffered saline solution (HBSS, minus 
Ca2+, Mg2+; Life Technologies Corporation, Grand Island, NY, USA). This 
suspension was transferred into a 15ml centrifuge tube, and then, spun at 300Xg 
for 2mins at 4oC. Supernatant was discarded, and tissue was processed into 
single-cell suspension by enzyme dissociation using Miltenyl’s adult brain 
dissociation kit (Miltenyl Biotec Inc., Auburn, CA, USA) according to the 
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manufacturer’s instructions. Following complete dissociation, cell suspension was 
applied to pre-wet MACS Smart Strainer (70μm; Miltenyl Biotec Inc., Auburn, CA, 
USA), and the flow through was processed for microglia labeling with CD11b+ 
microbeads (Miltenyl Biotec Inc., Auburn, CA, USA). Cells were washed with 2ml 
0.5% BSA in PBS buffer and centrifuged at 300Xg for 10mins at 4oC for removal 
of any unbounded beads from the pellet. Cell pellet was re-suspended in 500μl 
0.5% BSA in PBS buffer, and then applied onto a prepped MACS MS column 
attached to an OctoMACS magnetic separator (Miltenyl Biotec Inc., Auburn, CA, 
USA). Flow through containing unlabeled cells was collected first, and CD11b+ 
microglia were then collected by flushing out the magnetically labeled cells in the 
column into a microcentrifuge tube following the removal of the column from the 
magnetic separator. The flow through was immediately processed for astrocyte 
labeling using anti-ACSA-2 microbead kit (Miltenyl Biotec Inc., Auburn, CA, USA) 
according to the manufacturer’s instructions. In a similar way to the magnetic 
separation step in CD11b+ microglia isolation, ACSA-2+ astrocytes were also 
purified and collected.  
 
RNA extraction and purification 
Total RNA was extracted and purified from nucleus accumbal CD11b+ microglia 
and ACSA-2+ astrocytes using TRIzol (Invitrogen) and RNeasy Mini Kit (QIAGEN, 
Valencia, CA) according to manufacturer’s instructions. Similarly, RNA was also 
isolated and purified from nucleus accumbens tissues collected from animals in 
the 24-h and 48-h withdrawal experiments.   
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Library preparation  
For nucleus accumbal CD11b+ microglia and ACSA-2+ astrocytes, RNA 
sequencing libraries were prepared using the NuGEN Ovation RNA Ultra Low 
Input kit (500pg minimum) (Tecan Genomics Inc., Redwood City, CA) while RNA 
libraries for 24-h and 48-h withdrawal nucleus accumbens RNA samples were 
prepared using NEBNext Ultra II RNA Directional RNA Library Prep kit (NEB, 
Ipswich, MA).  
 
RNA sequencing 
Nucleus accumbal CD11b+ microglia and ACSA-2+ astrocytes libraries were 
indexed and sequenced as 2X75bp paired-end reads over 4 lanes on an Illumina 
HiSeq4000. For the 24-h and 48-h withdrawal experiment, nucleus accumbens 
RNA libraries were indexed and sequenced as 2X75bp paired-end reads using 
Illumina NextSeq500. 
 
Sequencing data preprocessing analyses 
To ensure there were no sequencing errors, demultiplexed fastq files from both 
Illumina HiSeq4000 and Illumina NextSeq500 were checked for quality using 
FastQC (v0.11.8). Reads that failed certain quality criteria were trimmed and 
filtered using BBDuk tool (sourceforge.net/projects/bbmap/) for quality 
improvement prior to the alignment step. Reads were then aligned to the mouse 
genome (mm10, downloaded from iGenomes, Illumina) using STAR aligner (Dobin 
et al 2013). Average input read counts were 53.75 million, 49.72 million, and 43.79 
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million for CD11b+ microglia, ACSA-2+ astrocytes, and nucleus accumbens tissue 
samples (24 h and 48 h) respectively. Average percentage of uniquely mapped 
reads were 74.96%, 73.96%, and 88.15% for CD11b+ microglia, ACSA-2+ 
astrocytes, and nucleus accumbens tissue samples (24 h and 48 h) respectively. 
Fragments counts were obtained using featureCounts (Liao et al 2014). Low read 
counts were filtered prior to differential expression analysis. 
 
Differential expression analyses 
DESeq2 (Love et al 2014) was used to assess differential gene expression (DGE) 
at a false discovery rate (FDR) < 0.2 and 0.25 for nucleus accumbens tissue 
samples (24 h and 48 h) and cell types (CD11b+ microglia and ACSA-2+ 
astrocytes), respectively.  
 
Principal component analysis and correlation analysis  
Principal component analysis and correlation analysis using hierarchical clustering 
function were performed to identify outliers in our samples.   
 
Pathway Enrichment Analysis 
Enrichr (Kuleshov et al 2016) was used in identifying and testing statistically 






3.4    RESULTS 
Experimental Design 
Three separate set of experiments were performed with the nucleus accumbens – 
the 24hWD, 48hWD, and 48hWD cell type-specific (astrocytes and microglia) 
experiments. Each experiment has three treatment groups – Saline, Nicotine and 
Withdrawal. The withdrawal mice in the 24hWD study were subjected to 24 h 
withdrawal while in the 48hWD study, mice undergoing withdrawal from nicotine 
were subjected to 48 h withdrawal. Nucleus accumbens tissues were utilized for 
both 24WD and 48hWD studies; however, these tissues were processed for cell 
sorting (microglia and astrocytes isolation/purification) in the cell type-specific 
experiment. RNA seq libraries were constructed for each of these experiments, 
and then sequenced (Figure 3.1a). 
 
Transcriptional alterations in the nucleus accumbens during 24 h and 48 h 
withdrawal from nicotine  
Given that symptoms associated with nicotine withdrawal are usually intense within 
24 - 48 h of abstinence (Stoker et al 2008), we examined temporal transcriptional 
changes in the nucleus accumbens of mice that underwent withdrawal for 24 h or 
48 h, in addition to their respective nicotine-treated and saline controls using RNA-
seq. For each of these treatment groups, we have 3 - 4 biological replicates. We 
compare the transcriptome profile of 24hWD (n=3) and 48hWD tissue samples 
(n=3) using a correlation matrix. Our data show that sample replicates of similar 
withdrawal timepoints are highly correlated (Spearman ‘s rank correlation, mean r 
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(24-h withdrawal replicates) = 0.93  ; Spearman ‘s rank correlation, mean r (48-h 
withdrawal replicates) = 0.84) while replicates across timepoints have low 
correlations (Spearman ‘s rank correlation, mean r (24-h withdrawal replicates vs 
48-h withdrawal replicates) = 0.33  ) (Figure 3.1b ). These data suggest a minimal 
overlap between differentially expressed genes (DEGs) at 24-h and 48-h 
withdrawal timepoints. However, while temporal transcriptional changes are 
expected during withdrawal from nicotine, it is important to note that our different 
library preparation approaches (Ribosomal depletion for 24hWD experiment; Poly-
A enrichment for 48hWD experiment) may have introduced further transcriptome 
variation between the 24hWD and 48hWD experiments. Next, we analyzed 
transcriptomic changes between treatment groups by performing pairwise 
differential gene expression (DGE) analysis (i.e. saline versus nicotine, saline 
versus withdrawal, and nicotine versus withdrawal). Genes that we statistically 
determined as differentially expressed are those with varying expression levels 
between treatment groups at false discovery rate (FDR) less than 0.2. This FDR 
cutoff was selected a priori since we do not expect large magnitude changes in 
brain transcriptome during chronic nicotine treatment and withdrawal. In the 
24hWD experiment, 207 genes (122 downregulated, 85 upregulated) were 
differentially expressed between saline and nicotine groups, 1050 DEGs (565 
downregulated, 485 upregulated) were revealed between saline and withdrawal 
groups, and the expression levels of 75 genes (25 downregulated, 50 upregulated) 
were altered between nicotine and withdrawal groups. However, in the 48hWD 
experiment, DGE analysis revealed 11 DEGs (3 downregulated, 8 upregulated) 
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between saline and nicotine groups, 653 DEGs (343 downregulated, 310 
upregulated) between saline and withdrawal groups, and 1485 DEGs (549 
downregulated, 936 upregulated) between nicotine and withdrawal groups. In 
order to visualize and identify statistically significant DEGs at our designated cutoff 
– fold changes (|log2FC| > 0.5) and adjusted p-values (FDR < 0.2), we generated 
a color-coded volcano plot for both 24hWD and 48hWD experiments, indicating 
upregulated genes in red and downregulated genes in blue (Figure 3.1c, i and ii). 
Further, we constructed a heatmap showing pairwise comparison of statistically 
significant DEGs between treatment groups. Our 24hWD data show there were no 
statistically significant DEGs between saline and nicotine; however, 63 (22 
downregulated, 41 upregulated) and 34 DEGs (5 downregulated, 29 upregulated) 
were statistically significant between saline and withdrawal, and nicotine and 
withdrawal groups, respectively (Figure 3.2a, i and ii.). Similarly, 48hWD pairwise 
comparison revealed 5 (2 downregulated, 3 upregulated), 359 (200 
downregulated, 159 upregulated), 972 (295 downregulated, 677 upregulated) 
statistically significant between saline and nicotine, saline and withdrawal, and 
nicotine and withdrawal groups, respectively (Figure 3.2b, i - iii). Pathway 
enrichment analysis of statistically significant DEGs indicates that genes involved 
in overrepresented pathways such as cholinergic synapse (Gng4, Gng2, Adcy8), 
glutamatergic synapse (Gng4, Gng2, Grik1, Adcy8), chemokine signaling (Gng4, 
Gng2, Adcy8), oxidative stress (Gpx3), glutathione metabolism (Gpx3) and nuclear 
receptors (Nr2f2, Rxrg) are upregulated during 24 h withdrawal (Figure 3.3a, i and 
ii ). Similarly, in our 48hWD experiment, genes associated with enriched pathways 
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such as fatty acid beta oxidation (Lpl), adipogenesis (Lpl), Alzheimer’s disease 
(Lpl), cholesterol metabolism (Lpl) and Tnf-alpha Nf-kβ signaling (Traip) were 
upregulated following nicotine treatment (Figure 3.3bi). Further analyses also 
revealed that genes upregulated during 48 h withdrawal timepoint are connected 
to enriched pathways such as inflammatory response (Thbs1,Tnfrsf1a, Col1a1), 
type II interferon signaling (Cybb, Isg15, Icam1, Ifit2, Prkcd, Gbp2b), microglia 
pathogen phagocytosis (Cybb, Trem2, Rac2, Cyba, Itgb2), macrophage markers 
(Rac2, Lyz2, Cd74, Cd83), complement and coagulation cascades (F2rl2, Itgb2, 
Serpind1, Serping1, C3, C2, C7, Cfb), complement activation and classical 
pathway (C3, C2, C7, C151) and TGFβ signaling (Lef1, Spp1, Smad9, Thbs1, 
Zfp423, Bmp4) (Figure 3.3b, ii and iii). In contrast to the enriched pathways that 
are altered during 24 h withdrawal timepoint, pathway analysis data at 48 h 
withdrawal timepoint showed perturbation of microglia-related pathways. 
Altogether, these data show temporal changes in nicotine withdrawal-induced 
transcriptional programs in the nucleus accumbens. 
 
Transcriptome remodeling in nucleus accumbal microglia and astrocytes 
during 48 h withdrawal from nicotine 
Non-neuronal cell types such as astrocytes and microglia are actively involved in 
the formation, maintenance and adaptations of neural circuitry (Allen & Barres 
2009). However, given possible disruption of molecular pathways related to 
microglia during 48 h withdrawal (as demonstrated by our pathway analysis), we 
evaluated nucleus accumbal microglia- and astrocyte-specific transcriptomic 
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changes during chronic nicotine and 48 h withdrawal. For this experiment, we 
generated 3 biological replicates (n =3) for each treatment – saline, nicotine and 
withdrawal. To arrive at each n, we pooled dissected nucleus accumbens tissues 
from 10 mice to improve our sample yield and maximize biological diversity. Then, 
we utilized magnetic activated cell sorting (MACS) for isolation and purification of 
microglia and astrocytes from pooled nucleus accumbens samples.  Purified ACSA 
II astrocytes and Cd11b+ microglia population were validated using quantitative 
PCR. Our validation of microglia showed enrichment of microglia markers (Cd11b, 
Tmem119 and P2ry12) in Cd11b+ microglia compared to total homogenate, liver 
and other brain cell types (previously shown in Chapter 2, Figure 2.7a. i - iii). 
Similarly, our astrocyte validation showed that astrocytes markers (Gfap and 
S100β) are highly expressed in ACSA II astrocytes population compared to total 
homogenate, liver and other brain cell types (Figure 3.4a, i and ii). RNA extracted 
from purified cell populations were checked for quality and we found that our 
samples’ RNA integrity number (RIN) range from 4.1 – 8.6. We constructed RNA-
seq libraries and performed deep sequencing on these libraries. To evaluate the 
reproducibility of our sequencing data and conservation across biological 
replicates, we computed correlations across all RNA-seq samples and found high 
correlations among Cd11b+ microglia (Spearman’s rank correlation, mean r = 0.77) 
or ACSA II astrocytes replicates (Spearman’s rank correlation, mean r = 0.70) and 
low correlations between both cell type replicates (Spearman’s rank correlation, 
mean r = 0.27). Hierarchical clustering of all RNA-seq samples in the correlation 
matrix revealed two samples, one from Cd11b+ microglia replicates and another 
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from ACSA II astrocytes replicates, as potential outliers (Figure 3.4b). This was 
further supported by our principal component analysis (PCA) data (Figure 3.4c, i 
and ii). Following outlier removal, we observed a tighter correlation within cell type 
replicates and a more distinct separation between cell type replicates (Figure 
3.4d). Then, we examined the purity of isolated brain cell types (microglia and 
astrocytes) by probing transcriptome data for expression of cell type-specific 
markers for microglia and astrocytes and found that these markers were highly and 
specifically expressed in their corresponding cell types (Figure 3.4e). To analyze 
microglia and astrocytes for treatment-related transcriptomic differences, we 
performed pairwise DGE analysis and created a heatmap representation of DEGs 
(cutoff = |log2FC| > 0.5, FDR < 0.25). In Cd11b+ microglia, 2458 genes (1009 
downregulated, 1449 upregulated) were differentially expressed following nicotine 
treatment; however, there was no significant transcriptomic alteration in ACSA II 
astrocytes under the same treatment condition (Figure 3.5 a). Further, in Cd11b+ 
microglia, DGE analysis revealed 31 DEGs (5 downregulated, 26 upregulated) 
between saline and withdrawal groups, and 32 DEGs (18 downregulated, 14 
upregulated) between nicotine and withdrawal groups (Figure 3.5a, ii and iii). 
However, in ACSA II astrocytes, 92 (42 downregulated, 50 upregulated) and 17 
genes (13 downregulated, 4 upregulated) were differentially expressed between 
saline and withdrawal, and nicotine and withdrawal groups, respectively (Figure 
3.5b, i and ii). Pathway analysis of DEGs obtained from pairwise DGE analysis of 
saline and nicotine Cd11b+ microglia shows that genes involved in enriched 
pathways such as TYROBP causal network, microglia pathogen phagocytosis, 
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type II interferon signaling, chemokine signaling, TGFβ signaling, IL-1 signaling, 
macrophage markers, toll-like receptor signaling, inflammatory response, and 
oxidative damage are downregulated while some of the upregulated genes are 
involved in overrepresented pathways like nicotine addiction and hypothetical 
network of drug addiction pathways (Figure 3.6ai). However, during 48 h 
withdrawal, pathway analysis showed that upregulated Cd11b+ microglia DEGs 
are involved in overrepresented pathways such as inflammation mediated by 
chemokine and cytokine signaling, toll-like receptor signaling, cytokine-cytokine 
receptor interaction, macrophage markers, and Tnf signaling (Figure 3.6a, ii and 
iii). Furthermore, pathway analysis of ACSA II astrocytes DEGs showed that genes 
that are upregulated during 48 h withdrawal are involved in overrepresented 
pathways including biogenic amine synthesis, taurine and hypotaurine 
metabolism, insulin secretion, butanoate metabolism, endocrine and other factor-
regulated calcium reabsorption, beta-alanine metabolism, and type I diabetes 
mellitus (Figure 3.6b, i and ii). Taken together, these data suggest that nicotine 
has a direct modulatory effect on microglia but not astrocytes. In addition, 48 h 
withdrawal from nicotine provokes microglial pro-inflammatory signaling while vital 
metabolic processes are disrupted in astrocytes. 
 
Comparison of DEGs in nucleus accumbens bulk tissue, microglia and 
astrocytes during chronic nicotine and withdrawal 
To identify and visualize both unique and overlapping DEGs between nucleus 
accumbens bulk tissue (24hWD and 48hWD experiments) and cell types 
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(astrocytes and microglia) during chronic nicotine and withdrawal, we constructed 
a Venn diagram and found that all DEGs resulting from pairwise DGE analysis of 
saline and nicotine in nucleus accumbens tissue and cell type-specific experiments 
were unique (no overlap) (Figure 3.7a). However, for pairwise DGE analysis of 
saline and withdrawal, we found 8 overlapping DEGs (Btg2, Syt17, Nr4a3, 
Slc6a11, Sparc, Gpr165, Nr2f2, Itih3) between 24hWD and 48hWD experiments, 
1 (Scn4b) between 24hWD and astrocytes, 2 (Tsc22d3, Pdk4) between 24hWD 
and microglia, 2 (Npas4, Pak6) between 48hWD and astrocytes, 3 (Mybpc1, Dio2, 
Gjb6) between 48hWD and microglia, and 1 (6330403K07Rik) between astrocytes 
and microglia experiments (Figure 3.7b). Further, two-way DGE analysis of 
nicotine and withdrawal produced overlapping DEGs between 24hWD and 48hWD 
(9 – Resp, Syt14, Ccdc108, Ngb, Gpx3, Gpr165, Nr2f2, Itih3, Pnoc), 48hWD and 
astrocytes (3 – Trf, Kcnj5, F2rl2), and 48hWD and microglia (4 – Doc2g, Unc13c, 
Plekhg3, Kif5a) experiments (Figure 3.7c). First, these data reveal nucleus 
accumbal gene programs that are consistently driving or contributing to nicotine 
withdrawal effects between 24 to 48 h withdrawal timeframe. In addition, these 
data uncover a subset of genes that are differentially expressed both in nucleus 
accumbens tissue and in either of the cell types evaluated at during nicotine 
withdrawal.  
 
3.5    DISCUSSION 
Transcriptional programs are genomic regulatory code instructing the formation, 
maintenance, and functions of diverse brain cell types and distinct brain structures. 
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Tissue- and cell type-specific evaluation of whole transcriptome can advance 
current understanding of the role of genes in CNS health and disorders such as 
nicotine dependence. In this study, we demonstrate that transcriptional programs 
are temporally-regulated in the nucleus accumbens during chronic nicotine and 
withdrawal. Additional investigation of transcriptome-wide responses to chronic 
nicotine treatment and withdrawal at cell-type specific resolution shows that unlike 
astrocytes, microglia are directly modulated by nicotine, resulting in myriad 
changes in microglial gene expression. Our cell type-specific RNA-seq data further 
show that during 48h withdrawal from nicotine, molecular pathways related to 
metabolic processes are overrepresented in astrocytes while pathways associated 
with inflammatory responses are overrepresented in microglia. Finally, during 
nicotine withdrawal, we find subset of genes that are enriched in nucleus 
accumbens tissue and either of the nucleus accumbens cell types examined. 
Taken together, our study provides the first insight into cell type-specific and 
tissue-level transcriptional remodeling in the nucleus accumbens in nicotine 
dependence.  
 
Temporal Transcriptional Changes in the Nucleus Accumbens during 
Nicotine Withdrawal 
Studies have shown that threshold levels of somatic signs and affective nicotine 
withdrawal symptoms such as anxiety increase 24 h post nicotine administration 
and completely wane by 96 h (Stoker et al 2008); however, transcriptional 
mechanisms underlying the development and brief maintenance of these 
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behavioral symptoms are still unknown. First, in our differential gene expression 
analysis data for saline versus nicotine, statistically significant enriched genes 
were only found at 48hWD but not at 24hWD experiment. This is most likely due 
to the variation in sequencing depth of our samples in both experiments since 
nicotine treatment period was the same in both studies. Additionally, only 5 DEGs 
were observed during nicotine treatment in the 48hWD experiment, suggesting 
more sequencing depth is required in our 24hWD experiment to observe such a 
small change. Lpl and Traip are part of the upregulated DEGs following nicotine 
treatment. We found Lpl in overrepresented pathways related to lipid metabolism 
and transport while Traip is associated with Tnfα-Nfkβ signaling pathway. It is 
suggested that reduced Lpl levels may contribute to neurite pathology and reduced 
neurogenesis potential in Alzheimer’s (Gong et al 2013)  while Traip has been 
shown to inhibit activation of Nfkβ mediated by Tnfα (Lee et al 1997). This suggest 
upregulation of both genes during nicotine treatment may be neuroprotective. 
Furthermore, our whole transcriptome studies show distinct gene programs in the 
nucleus accumbens at 24 h and 48 h withdrawal timepoints. These findings 
suggest that temporal transcriptional changes may underlie differential emergence 
and diminishing thresholds of behavioral symptoms during the early periods of 
nicotine withdrawal. However, further analyses show that a total (pairwise DGE 
analysis between saline and withdrawal = 8 genes, and nicotine and withdrawal = 
9 genes) of 14 unique enriched genes (Resp18, Sytl4, Ccdc108, Ngb, Gpx3, 
Gpr165, Nr2f2, Itih3, Pnoc, Btg2, Syt17, Nr4a3, Slc6a11, Sparc) overlap between 
DEGs at 24 h and 48 h withdrawal timepoints. These genes all have similar 
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directionality (all upregulated) during 24 h and 48 h withdrawal, except for 
Ccdc108, Syt17 and Nr4a3 that were upregulated at 24 h but downregulated at 48 
h, and Btg2 that was consistently downregulated regardless of withdrawal period.  
Interestingly, a number of these genes (Gpx3, Itih3, Ngb) have been shown to 
respond to oxidative stress conditions (Herault et al 2012, Maes et al 2011, Wang 
et al 2007, Watanabe et al 2012, Wickramasekara et al 2018), suggesting their 
upregulation indicates oxidative imbalance during nicotine withdrawal. This is 
further supported by increased Sparc expression, which is connected to elevation 
of reactive oxygen species (ROS). Sparc gene deletion or deficiency have been 
shown to have protective effect against oxidative stress (Aseer et al 2017, Peixoto 
et al 2016). In addition, studies have shown that Btg2 is a coactivator for Nrf2 in 
upregulating cellular antioxidant defenses (Karve & Rosen 2012); however, Btg2 
was downregulated at 24 h and 48 h nicotine withdrawal timepoints. These findings 
further suggest altered ROS homeostasis during nicotine withdrawal. One distinct 
transcriptomic feature observed during 48 h withdrawal but not evident in 24 h 
withdrawal is the enrichment of signaling pathways related to microglial pro-
inflammatory cascades. Taken together, further studies may lead to transcriptomic 
characterization of molecular events associated with behavioral symptomatology 






Transcriptome Remodeling in Microglia during Chronic Nicotine and 
Withdrawal 
Recently, microglia have emerged as central players in many brain disorders 
(Salter & Stevens 2017), including drug addiction (Lewitus et al 2016b, Schwarz & 
Bilbo 2013, Schwarz et al 2013); however, their role in nicotine dependence is 
completely unknown. To study microglial transcriptomic changes in response to 
chronic nicotine and withdrawal, we utilized cell type-specific RNA-seq. Our bulk 
tissue RNA-seq studies capture RNAs from all cell types en masse; therefore, 
transcriptomic composition of individual cell types is diluted and missed. First, our 
data suggest that nicotine directly interacts with microglia, provoking myriad 
transcriptome remodeling.  
One of the notable changes is the upregulation of α4 and β2 nAChR subunits 
following nicotine treatment. Further analysis revealed that both genes are part of 
the nicotine addiction pathway, which is overrepresented in microglia. Our findings 
show that α4β2 nAChR is upregulated in microglia in response to nicotine 
treatment, suggesting a direct mechanism through which nicotine interacts with 
microglia.  Prior to this study, it is unclear whether or how nicotine interacts with 
microglia. However, in contrast to our study, previous studies evaluating nicotine’s 
effect on microglia using immortalized cell lines or primary microglial cultures have 
reported the expression of homomeric α7-nAChR on microglia (De Simone et al 
2005, King et al 2017, Mencel et al 2013, Shytle et al 2004, Suzuki et al 2006), 
suggesting nicotine may directly interact with this receptor subtype on microglia to 
elicit its effect. While these studies may have provided mechanistic insights into 
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nicotine’s modulation of microglia, it is noteworthy that our approach, which 
involves isolation and purification of microglia from fresh nucleus accumbens 
tissue, presents microglia in a more natural state and provides better translatability 
to in vivo situations. Another important consideration is the differences in brain 
region from which microglia was prepared or isolated, as nAChR subtypes are 
differentially expressed across brain regions. Furthermore, nicotine can also have 
an indirect modulatory effect on microglia through enhancement of neuron-
microglia communication. One of the important bidirectional communication 
between neurons and microglia is the interaction between fractalkine, Cx3cl1, 
which is constitutively expressed in neurons and its receptor, Cx3cr1, which is 
primarily expressed on microglia. Cx3cl1-Cx3cr1 signaling is required to keep 
microglia in a surveying phenotype, and activation of Cx3cr1 provokes signal 
cascades that modulates apoptotic, proliferative, transcriptional and migratory 
functions in microglia (Szepesi et al 2018). However, our findings show that Cx3cr1 
and other chemokines that could mediate neuron-microglia communication (Ccl2, 
Ccl12, and CxCl9) were all downregulated following nicotine treatment, reinforcing 
our previous findings. Furthermore, our data show that overrepresented pathways 
including inflammatory responses, oxidative damage, toll-like receptor signaling, 
macrophage markers, and microglia pathogen phagocytosis are downregulated in 
microglia following nicotine treatment. These findings support previous studies that 
have demonstrated nicotine’s neuroprotective property in neurodegenerative 
disorders such as Alzheimer’s (Newhouse et al 2012, Wilson et al 1995) and 
Parkinson’s (Villafane et al 2007), two disorders with extensive links to microglial 
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activation and inflammatory responses (Amor et al 2010). However, during 48 h 
nicotine withdrawal, enriched pathways such as inflammation mediated by 
chemokine and cytokine signaling, toll-like receptor signaling, macrophage 
markers are upregulated in microglia, suggesting nicotine withdrawal-induced 
microglial pro-inflammatory signaling as well as microglia proliferation. Overall, 
these data provide evidence for nicotine’s direct modulatory effect on microglia as 
well as its suppression of microglial pro-inflammatory networks, which were all 
activated during nicotine withdrawal.     
 
Transcriptome Remodeling in Astrocytes during Chronic Nicotine and 
Withdrawal 
Astrocytes are actively involved in regulating the overall architecture and activity 
of neuronal circuits (Szepesi et al 2018). While the role of astrocytes have been 
studied in addiction to some drugs of abuse (Goins & Bajic 2018, Ikeda et al 2010, 
Turner et al 2013a), their contributions in nicotine dependency is still unclear. We 
found no enriched genes in astrocytes following nicotine treatment, suggesting that 
nicotine does not have a direct modulatory effect on astrocytes. However, during 
nicotine withdrawal, numerous genes were differentially expressed, suggesting 
astrocyte reactivity to withdrawal-related insults within their local 
microenvironment. Further, our data show that overrepresented pathways 
including biogenic amine synthesis, taurine and hypotaurine metabolism, 
butanoate metabolism, beta-alanine metabolism and iron homeostasis are 
upregulated in astrocytes, suggesting that astrocytes upregulate these metabolic 
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pathways in response to withdrawal-related insults on neurons. Usually, astrocytes 
optimize their metabolism to provide energy to the neurons that are deprived of 
nutrients upon insult. These metabolic changes that astrocyte develop following 
neuronal insult are one of the defining features of reactive astrocytes (Ben Haim 
et al 2015, Iglesias et al 2017).  Our data show that GAD1 and GAD2 (both 
glutamate decarboxylases), which are both upregulated in our study, are involved 
in many of the metabolic processes overrepresented in astrocytes during nicotine 
withdrawal. GADs deplete glutamate levels in the brain to produce gamma 
aminobutyric acid (GABA). Therefore, GAD upregulation may indicate alterations 
in glutamate homeostasis and elevated GABA levels, which are both features 
associated with reactive astrocyte (Ben Haim et al 2015). In fact, a study reported 
that astrocytes can modulate microglia activity via GABA release (Lee et al 2011). 
On the other hand, this supports the concept that astrocyte reactivity may be a 
response to activated microglia, and not necessarily a direct response to neuronal 
insult. Altogether, our astrocyte transcriptome data suggest that astrocyte undergo 
transformation to the reactive phenotype, which may be a response to neuronal 










3.6    FIGURES 
 
Figure 3.1. Differentially expressed genes in the nucleus accumbens during chronic 
nicotine and withdrawal. a. Experimental design. b. Correlation matrix showing 
relationships between withdrawal samples from 24hWD and 48hWD experiment. c. 














Figure 3.2. Distinct gene programs are altered in the nucleus accumbens of mice in 
the 24hWD and 48hWD experiments.  
Heat map representation showing differentially expressed genes obtained from pairwise 
DGE analysis of a. 24hWD experiment i) Sal (Saline) and 24 h withdrawal (24hWD), ii) 
Nic (Nicotine) and 24 h withdrawal. b. 48hWD experiment i) Sal and Nic, ii) Sal and 48 h 











Figure 3.3. Overrepresented pathways in the nucleus accumbens during chronic 
nicotine and withdrawal in the 24hWD and 48hWD experiments.  
Pathway enrichment analysis highlighting some of the overrepresented pathways in a. 
24hWD experiment i) Sal and 24 h withdrawal, ii) Nic and 24 h withdrawal. b. 48hWD 










Figure 3.4. Evaluating the reproducibility of our data and conservation across 
biological replicates. a. Bar graph showing quantitative PCR analysis of astrocytes 
markers in the liver, brain cell-types and tissue (Total homogenate). i) Gfap, ii) S100b. b. 
Correlation matrix showing relationships between nucleus accumbal Cd11b+ microglia and 
ACSA II astrocytes samples. Sample clustering identify two potential outliers (in red-
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colored asterisks). c. Separate principal component analysis plot showing variation 
between i) Cd11b+ microglia, ii) ACSA II astrocytes samples. Potential outlier samples 
(same samples observed in 3.4b) are encircled by the red-colored ring. d. Correlation 
matrix showing relationships between nucleus accumbal Cd11b+ microglia and ACSA II 
astrocytes samples post-outlier removal. e. Heatmap showing the expression of classical 
















Figure 3.5. Transcriptional programs in nucleus accumbal Cd11b+ microglia and 
ACSA II astrocytes during chronic nicotine and 48 h withdrawal.  
Heat map representation showing differentially expressed genes obtained from pairwise 
DGE analysis of a. Cd11b+ microglia i) Sal and Nic, ii) Sal and 48 h withdrawal, iii) Nic and 








Figure 3.6. Overrepresented pathways in nucleus accumbal Cd11b+ microglia and 
ACSA II astrocytes during chronic nicotine and 48 h withdrawal.  
Pathway enrichment analysis showing some of the overrepresented pathways in a. 
Cd11b+ microglia i) Sal and Nic, ii) Sal and 48 h withdrawal, iii) Nic and 48 h withdrawal. 

















Figure 3.7. Graphical overview of unique and overlapping differentially expressed 
gene in all RNA sequencing experiments.  
Venn diagram showing relationships between differentially expressed genes in a. Sal and 





Neurons are the primary research target in the exploration and development of 
novel smoking cessation pharmacotherapies. These investigations have led to the 
discovery and development of three FDA-approved smoking cessation aids – 
nicotine replacement therapy, varenicline, and bupropion, each of which elicit their 
effects via modulation of neuronal function. However, while each of these 
therapeutics have quantifiable success as smoking cessation aids, about 80% of 
smokers attempting to quit still fail. This may be substantially due to inability of 
these current aids to address some critical aspects of nicotine dependency. 
Therefore, there is an urgent need to extend attention to non-neuronal cell types 
such as astrocytes and microglia, which are both active participants in neuroplastic 
events underlying drug addiction. This chapter will highlight the salient aspects of 
this study and recommend experimental approaches to advance this project.   
 
4.1    CHAPTER 2 SUMMARY 
In Chapter 2, we conducted series of experiments that demonstrated a link 
between oxidative stress signaling and nicotine withdrawal-related anxiety. 
Neurons are particularly susceptible to oxidative stress insults, and it is thought 
that these insults can activate neuronal signaling pathways that are associated 
with the development of anxiety-like behavior during nicotine withdrawal. Our
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results showed that both pro-inflammatory signaling and oxidative stress during 
nicotine withdrawal are limited to the nucleus accumbens, which has a critical role 
in anxiety. Given that Nox system is the major source of intracellular ROS and 
Nox2 subtype is primarily expressed in microglia, we hypothesized that oxidative 
stress and nicotine withdrawal-related anxiety are direct consequences of 
microglial morphological remodeling. Our findings provide the first evidence of 
microglial involvement in nicotine dependence.  
 
Future direction  
While our molecular findings were based on the evaluation of striatum, our 
behavioral data may result from molecular events within multiple neural substrates 
of anxiety. Therefore, future studies may need to examine other neural substrates 
of anxiety for the same molecular events (pro-inflammatory signaling, oxidative 
stress, microglial morphological remodeling) observed in the nucleus accumbens 
during nicotine withdrawal. Additional studies should also include region-specific 
depletion of microglia or inhibition of microglia functions such as their pro-
inflammatory signaling prior to behavioral and molecular assessments. Together, 
this will elucidate brain regions that are actually associated with nicotine-
withdrawal related anxiety.  
 
4.2    CHAPTER 3 SUMMARY 
Based on our findings in chapter 2, we extended our study to capture tissue-level 
transcriptome changes in the nucleus accumbens during chronic nicotine and 
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withdrawal (24 h and 48 h). This study uncovered temporal transcriptome changes 
during the early stages of withdrawal (24 h to 48 h). Interestingly, we found a 
substantial proportion of overlapping genes at these withdrawal timepoints to be 
associated with dysregulation of ROS homeostasis and oxidative imbalance. This 
corroborates our findings in chapter 2. More specifically, during 48 h withdrawal, 
we found enrichment of gene subsets connected to microglia pro-inflammatory 
signaling pathways. 
         To have a finer resolution that aid better characterization of transcriptomic 
changes during chronic nicotine and withdrawal, we performed cell type-specific 
RNA sequencing (RNA-seq) and evaluated astrocyte- and microglia-specific 
transcriptome changes during chronic nicotine and 48 h withdrawal. In contrast to 
previous suggestions of α7 nAChR on microglia, we identified α4β2 nAChR as the 
potential receptor through which nicotine interacts directly with microglia. Chronic 
nicotine treatment suppresses pro-inflammatory pathways in microglial 
transcriptome while 48 h withdrawal activates them. This is consistent with many 
studies assessing neuroinflammation in neurodegenerative disorders. For 
astrocytes, we found that nicotine has no impact on their transcriptome; however, 
during 48 h withdrawal, metabolic pathways in astrocytes are activated. Nicotine’s 
activation of microglia but not astrocytes, and the type of responses from both cell 
types during withdrawal present a consistent pattern with several studies that 
demonstrated that activated microglia promotes reactive astrocytes in many 
neurodegenerative diseases (Liu et al 2011). 
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         Compared to our nucleus accumbens tissue RNA-seq, astrocytes- and 
microglia-specific RNA-seq gave us a less complex insight into the transcriptomic 
changes observed at tissue-level during chronic nicotine and withdrawal. 
 
Future direction  
Future studies can include weighted correlation network analysis or weighted gene 
co-expression network analysis (WGCNA) to determine clusters (modules) of 
highly correlated genes in our enriched gene datasets (tissue and cell type-
specific). Correlation networks aid network-based gene screening approaches that 
can be used to determine candidate biomarkers or therapeutic targets. These 
biomarkers or gene targets from WGCNA can then be validated using quantitative 
PCR. Following validation, functional genomics studies should be performed to 
study the function of these targets, as well as their impact on nicotine withdrawal-
relevant behavioral phenotypes. 
         Finally, moving biomarkers or gene targets with therapeutic potential from 
the laboratory to the point at which it is available as a medication is a long, rigorous 
and expensive process. However, going forward, we do not doubt the 
translatability of our findings given that certain modulators of microglia 
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APPENDIX A  
CODE FOR RNA SEQUENCING ANALYSIS 
################################################################ 
#################RNA-Seq Data Analysis Pipeline on UNIX ############# 
#mm10 genome was downloaded from iGenomes 
#https://support.illumina.com/sequencing/sequencing_software/igenome.html 
 
#Generating genome indexes 
module load gcc/4.9.1 
module load star/2.5 
 
STAR --runThreadN 20 --runMode genomeGenerate --genomeDir 
/work/adeluyi/mm10genome_indexes --genomeFastaFiles 
/work/adeluyi/mm10genome/mm10genome.fa --sjdbGTFfile 
/work/adeluyi/mm10genome/mm10genes.gtf --sjdbOverhang 75 
 
#Checking read quality using FastQC 
module load fastqc/0.11.5 
 
for i in /work/adeluyi/input_folder/cat_files/*fastq.gz; 





#For reads that need adapter trimming  
module load bbmap/gcc/38.16 
 
for i in `ls -1 /work/adeluyi/input_folder/ fastq_file/*_1.fastq.gz | sed 
's/_1.fastq.gz//'` 
do bbduk.sh in1=$i\_1.fastq.gz in2=$i\_2.fastq.gz  









TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT tbo tpe 
done 
 
#Mapping reads to genome 
module load gcc/4.9.1 




for i in $(ls /work/adeluyi/input folder/cat_files | sed s/_[12].fastq.gz// | sort -u); 
 
do STAR --genomeDir /work/adeluyi/mm10genome_indexes --readFilesIn 
/work/adeluyi/input folder/cat_files/${i}_1.fastq.gz 
/work/adeluyi/input_folder/cat_files/${i}_2.fastq.gz  
--runThreadN 20 --outFileNamePrefix 
/work/adeluyi/output_folder/mapped_reads/$i.  
--sjdbGTFfile /work/adeluyi/mm10genome/mm10genes.gtf  
--sjdbOverhang 75 --readFilesCommand zcat; 
done 
 
#Read count and summarization 
module load subread/1.5.3 
 












################ Statistical Data Analysis on R Software################# 
#For this part, I am using the analysis of NAc48hWD experiment as an example. 
Other experiments (NAc24hWD, Microglia-specific and Astrocyte-specific 
experiments) were passed through the same analysis pipeline. 
 
NAc = read.csv("NAc48hWD_count.csv", header = T) 
head(NAc) 
 
####### Filter out low read counts 
lowread = apply(NAc,1,max) 
whcount = which(lowread<5) 
length(whcount) 
NAc_data = NAc[-whcount,] 
dim(NAc_data) 
rownames(NAc_data) = NAc_data$Geneid 
head(NAc_data) 








rownames(NAc_data1) = NAc_data1$Gene 
head(NAc_data1) 
NAc_data1 = NAc_data1[,-1] 
head(NAc_data1) 
Nlen = as.vector(NAc_data$Length) 
 
########## Differential Expression Analysis  




















plotMA(res_NAc, main="MA Plot with DESeq2: 48hWD Nicotine Studies") 
tsig_NAc = table(res_NAc[,6]<0.2) 
tsig_res_NAc = which(res_NAc[,6]<0.2) 









write.csv(DEG,"NAc_DEG(48hWD).csv", row.names = FALSE) 
NAc48hWD_cutoff = DEG[DEG$log2FC>0.5|DEG$log2FC < -0.5,] 
write.csv(NAc48hWD_cutoff,"NAc48hWD_cutoff.csv", row.names = FALSE) 
 
############ PCA plot  
N_rld <- rlog(NAc_dds1, blind=FALSE) 












# Cutoff for differential expression 
fc = 0.5 
cf = -0.5 



















Nlog_res$neglogFDR> -log10(pval), "Upregulated", ifelse(Nlog_res$log2FC<cf & 
Nlog_res$neglogFDR> -log10(pval),"Downregulated”,” Not significant"))) 
table(N_resmut$Expression) 
head(N_resmut) 
volc=ggplot(na.omit(N_resmut)) + aes(x=log2FC, y=-log10(qvalue)) +  
geom_point(aes(color = Expression),alpha=0.65) +   
scale_color_manual(values = c("blue","grey40","firebrick3")) + xlim(c(-6.5, 6)) + 
ylim(c(0,5)) +  
ggtitle("VOLCANO PLOT","Differentially Expressed Genes")+ 
geom_vline(xintercept = c(-0.5,0.5), colour = "grey30") +  
geom_hline(yintercept = 0.69, colour = "grey30") + 
theme(plot.background = element_rect(), panel.grid.major=element_blank(), 
panel.grid.minor=element_blank(),panel.background=element_rect(fill = "white"))  
 
volc+geom_text_repel(data=N_genes, aes(label = Gene), size = 5, 
         box.padding = unit(0.5, "lines"), 





###########Transcript per million (TPM) normalization 
tpm <- function(coun,leng) { 
  x <- coun/leng 
  return(t(t(x)*1e6/colSums(x))) 
} 
N_TPM = tpm(NAc_data1, Nlen) 
head(N_TPM) 
 




#For All Genes 
N_TPM = as.data.frame(N_TPM) 
head(N_TPM) 
N_TPMmeans = rowMeans(N_TPM) 
head(N_TPMmeans) 
N_TPMsd<- vector(length=nrow(N_TPM), mode="numeric")  









N_annot = data.frame(Sample = factor(rep(c("Sal","Nic","48hWD"),c(4,3,3)))) 
N_ann = list(Sample = c(Sal="grey80",Nic="grey50","48hWD" ="darkgreen")) 
rownames(N_annot) = colnames(N_TPMpheat) 
pheatmap(N_TPMpheat, cluster_cols = FALSE,gaps_col = c(4,7),labels_col = 
c("","","","","","","","","",""),color = colorRampPalette(c("navy","white","firebrick3" 
))(50),annotation_col = N_annot, annotation_colors = N_ann) 
 
# Extracting DEGs (that passed the cutoff) from the matrix 
N_TPM1 = NAc_data1[rownames(NAc_data1)%in%NAc48hWD_cutoff$Gene,] 
Nlen1 = NAc[NAc$Geneid %in% NAc48hWD_cutoff$Gene,] 
Nlen1 = Nlen1$Length 
N_TPM1 = tpm(N_TPM1,Nlen1) 
head(N_TPM1) 
N_TPM2 = as.data.frame(N_TPM1) 
head(N_TPM2) 
N2_TPMmeans = rowMeans(N_TPM2) 
head(N2_TPMmeans) 
N2_TPMsd<- vector(length=nrow(N_TPM2), mode="numeric")  








N_annot = data.frame( Sample = factor(rep(c("Sal","Nic","48hWD"),c(4,3,3)))) 
N_ann = list(Sample = c(Sal="grey80",Nic="grey50","48hWD" ="darkgreen")) 
rownames(N_annot) = colnames(N_pheat) 
pheatmap(N_pheat,cluster_cols=FALSE,gaps_col=c(4,7),cutree_rows=2,labels_
col=c("","","","","","","","","",""),color=colorRampPalette(c("navy","white","firebrick3" 
))(50),annotation_col = N_annot, annotation_colors = N_ann) 
 
##########Two-way Analysis  
#Extracting the dataframe of sample treatments to be compared from the 
dataframe containing all samples  
NAc_SN = NAc_data1[,-(8:10)] 
head(NAc_SN) 
NAc_SWD = NAc_data1[,-(5:7)] 
head(NAc_SWD) 
NAc_NWD = NAc_data1[,-(1:4)] 
head(NAc_NWD) 
SN_col = NAc_col[-(8:10),] 
head(SN_col) 




NWD_col = NAc_col[-(1:4),] 
head(NWD_col) 
 
####### Sal vs Nic 





plotMA(res_SN, main="MA Plot with DESeq2: 48hWD Nicotine Studies") 
tsig_SN = table(res_SN[,6]<0.2) 
tsig_res_SN = which(res_SN[,6]<0.2) 
sig_SN = res_SN[tsig_res_SN,] 
head(sig_SN) 
 





write.csv(SN_DEG,"Sal_Nic_DEG(48hWD).csv", row.names = FALSE) 
SN48hWD_cutoff = SN_DEG[SN_DEG$log2FC>0.5|SN_DEG$log2FC < -0.5,] 
write.csv(SN48hWD_cutoff,"Sal_Nic(48hWD)cutoff.csv", row.names = FALSE) 
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####### Sal vs 24hWD 





plotMA(res_SWD, main="MA Plot with DESeq2: 48hWD Nicotine Studies") 
tsig_SWD = table(res_SWD[,6]<0.2) 
tsig_res_SWD = which(res_SWD[,6]<0.2) 
sig_SWD = res_SWD[tsig_res_SWD,] 
head(sig_SWD) 
 





write.csv(SWD_DEG,"Sal_WD_DEG(48hWD).csv", row.names = FALSE) 
SWD48hWD_cutoff = SWD_DEG[SWD_DEG$log2FC>0.5|SWD_DEG$log2FC < 
-0.5,] 





####### Nic vs 24hWD 





plotMA(res_NWD, main="MA Plot with DESeq2: 48hWD Nicotine Studies") 
tsig_NWD = table(res_NWD[,6]<0.2) 
tsig_res_NWD = which(res_NWD[,6]<0.2) 
sig_NWD = res_NWD[tsig_res_NWD,] 
head(sig_NWD) 
 





write.csv(NWD_DEG,"Nic_WD_DEG(48hWD).csv", row.names = FALSE) 
NWD48hWD_cutoff = NWD_DEG[NWD_DEG$log2FC>0.5|NWD_DEG$log2FC < 
-0.5,] 






# Determining overlapping genes between experiments. The output was used for  
the construction of Venn Diagram. 
SN24hWD = No DEGs at the cutoff 
SWD24hWD = read.csv("Sal_WD(24hWD)cutoff.csv", header = T) 
NWD24hWD = read.csv("Nic_WD(24hWD)cutoff.csv", header = T) 
SN48hWD = read.csv("Sal_Nic(48hWD)cutoff.csv", header = T) 
SWD48hWD = read.csv("Sal_WD(48hWD)cutoff.csv", header = T) 
NWD48hWD = read.csv("Nic_WD(48hWD)cutoff.csv", header = T) 
SN_Mic = read.csv("Microglia_SN DEGs (Untrimmed).csv", header = T) 
SWD_Mic = read.csv("Microglia_SWD DEGs (Untrimmed).csv", header = T) 
NWD_Mic = read.csv("Microglia_NWD DEGs (Untrimmed).csv", header = T) 
SN_Ast = No DEGs at the cutoff 
SWD_Ast = read.csv("Astrocytes_SWD DEGs (Untrimmed).csv", header = T) 
NWD_Ast = read.csv("Astrocytes_NWD DEGs (Untrimmed).csv", header = T) 
 
######## SAL vs NIC 
# Two-way Sal/Nic in NAc48hWD experiment vs Microglia48hWD experiment 
SN_Mic_48hWD_tab = table(SN48hWD$Gene %in% SN_Mic$X) 






######## SAL vs WD 
# Two-way Sal/WD in NAc24hWD experiment vs NAc48hWD experiment 
SWD_24h_48hWD_tab = table(SWD24hWD$Gene %in% SWD48hWD$Gene) 
SWD_24h_48hWD_overlap = SWD24hWD$Gene[which(SWD24hWD$Gene 
%in% SWD48hWD$Gene)] 
 
# Two-way Sal/WD in NAc24hWD experiment vs Astrocytes48hWD experiment 
SWD_Ast_24hWD_tab = table(SWD24hWD$Gene %in% SWD_Ast$X) 
SWD_Ast_24hWD_overlap = SWD24hWD$Gene[which(SWD24hWD$Gene 
%in% SWD_Ast$X)] 
 
# Two-way Sal/WD in NAc24hWD experiment vs Microglia48hWD experiment 
SWD_Mic_24hWD_tab = table(SWD24hWD$Gene %in% SWD_Mic$X) 
SWD_Mic_24hWD_overlap = SWD24hWD$Gene[which(SWD24hWD$Gene 
%in% SWD_Mic$X)] 
 
# Two-way Sal/WD in NAc48hWD experiment vs Astrocytes48hWD experiment 
SWD_Ast_48hWD_tab = table(SWD48hWD$Gene %in% SWD_Ast$X) 
SWD_Ast_48hWD_overlap = SWD48hWD$Gene[which(SWD48hWD$Gene 
%in% SWD_Ast$X)] 
 
# Two-way Sal/WD in NAc48hWD experiment vs Microglia48hWD experiment 
SWD_Mic_48hWD_tab = table(SWD48hWD$Gene %in% SWD_Mic$X) 
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SWD_Mic_48hWD_overlap = SWD48hWD$Gene[which(SWD48hWD$Gene 
%in% SWD_Mic$X)] 
# Two-way Sal/WD in Astrocytes48hWD experiment vs Microglia48hWD 
experiment 
SWD_Mic_Ast_tab = table(SWD_Ast$X %in% SWD_Mic$X) 
SWD_Mic_Ast_overlap = SWD_Ast$X[which(SWD_Ast$X %in% SWD_Mic$X)] 
 
######## NIC vs WD 
# Two-way Nic/WD in NAc24hWD experiment vs NAc48hWD experiment 
NWD_24h_48hWD_tab = table(NWD24hWD$Gene %in% NWD48hWD$Gene) 
NWD_24h_48hWD_overlap = NWD24hWD$Gene[which(NWD24hWD$Gene 
%in% NWD48hWD$Gene)] 
 
# Two-way Nic/WD in NAc24hWD experiment vs Astrocytes48hWD experiment 
NWD_Ast_24hWD_tab = table(NWD24hWD$Gene %in% NWD_Ast$X) 
NWD_Ast_24hWD_overlap = NWD24hWD$Gene[which(NWD24hWD$Gene 
%in% NWD_Ast$X)] 
 
# Two-way Nic/WD in NAc24hWD experiment vs Microglia48hWD experiment 
NWD_Mic_24hWD_tab = table(NWD24hWD$Gene %in% NWD_Mic$X) 





# Two-way Nic/WD in NAc48hWD experiment vs Astrocytes48hWD experiment 
NWD_Ast_48hWD_tab = table(NWD48hWD$Gene %in% NWD_Ast$X) 
NWD_Ast_48hWD_overlap = NWD48hWD$Gene[which(NWD48hWD$Gene 
%in% NWD_Ast$X)] 
 
# Two-way Nic/WD in NAc48hWD experiment vs Microglia48hWD experiment 
NWD_Mic_48hWD_tab = table(NWD48hWD$Gene %in% NWD_Mic$X) 
NWD_Mic_48hWD_overlap = NWD48hWD$Gene[which(NWD48hWD$Gene 
%in% NWD_Mic$X)] 
 
# Two-way Nic/WD in Astrocytes48hWD experiment vs Microglia48hWD 
experiment 
NWD_Mic_Ast_tab = table(NWD_Ast$X %in% NWD_Mic$X) 
NWD_Mic_Ast_overlap = NWD_Ast$X[which(NWD_Ast$X %in% SWD_Mic$X)] 
 
################################################################ 
# Correlation analysis between samples 
install.packages("corrplot") 
library("corrplot") 
col4 <- colorRampPalette(c("#053061","#053061","#053061","white","darkred")) 
 
#For the withdrawal group from 24hWD and 48hWD experiments 
twentyfour = dataframe of withdrawal group from 24hWD experiment 
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fortyeight = dataframe of withdrawal group from 24hWD experiment 
vec = unique(rbind(twentyfour, fortyeight)) 
WD_cor = cor(vec[,c(8:10,18:20)], method = "spearman") 
WD_cor1 = ((WD_cor) + 1)/2 
head(WD_cor1) 
corrplot(WD_cor1,method="shade",cl.lim=c(0,1),col=col4(20),cl.cex=1.3,addgrid.
col = "grey") 
 
#For the cell type-specific (astrocytes and microglia) experiment 
cell = dataframe of astrocytes and microglia samples combined 
cell_cor = cor(cell, method = "spearman")  
cell_co = ((cell_cor) + 1)/2 
head(cell_co) 
 
#Without clustering option 
corrplot(cell_co,method="shade",cl.lim=c(0,1),col=col4(20),cl.cex=1.3,addgrid.col 
= "grey") 
#With hierarchical clustering option 
corrplot(cell_co,method="shade",cl.lim=c(0,1),col=col4(20),cl.cex=1.3,addgrid.col 
= "grey",order = "hclust", hclust.method = "median") 
#Removing outliers and re-plotting 
cell_cor1 = cell_co[-c(5,10),-c(5,10)] 
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corrplot(cell_cor1, method = "shade", cl.lim = c(0,1), col = col4(20) ,cl.cex = 
1.3,addgrid.col = "grey") 
 
################################################################ 




cellTPMZscore1 = Z-score dataframe for astrocytes and microglia samples 
cell2 = cellTPMZscore1[rownames(cellTPMZscore1) %in% gene,] 
head(cell2) 
cell2a = cell2[,-c(5,10)] 
cell3 = as.matrix(cell2a) 
cell_annot = data.frame(Sample = factor(rep(c("Microglia","Astrocytes"),c(8,8)))) 
cell_ann = list(Sample = c(Microglia ="darkgreen", Astrocytes ="grey10")) 
rownames(cell_annot) = colnames(cell3) 
pheatmap(cell3,cluster_cols=FALSE,gaps_col=c(8),color=colorRampPalette(c("d
arkblue","white","brown"))(50),annotation_col = cell_annot, annotation_colors = 
cell_ann) 
 
 
 
